BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20:3898-3941. [PMID: 25738536 DOI: 10.3390/molecules20033898] [Cited by in Crossref: 415] [Cited by in F6Publishing: 415] [Article Influence: 59.3] [Reference Citation Analysis]
Number Citing Articles
1 Ali S, Hamam D, Liu X, Lebrun J. Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. Front Endocrinol 2022;13:993570. [DOI: 10.3389/fendo.2022.993570] [Reference Citation Analysis]
2 Tamanini E, Miyamura S, Buck IM, Cons BD, Dawson L, East C, Futamura T, Goto S, Griffiths-jones C, Hashimoto T, Heightman TD, Ishikawa S, Ito H, Kaneko Y, Kawato T, Kondo K, Kurihara N, Mccarthy JM, Mori Y, Nagase T, Nakaishi Y, Reeks J, Sato A, Schöpf P, Tai K, Tamai T, Tisi D, Woolford AJ. Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00272] [Reference Citation Analysis]
3 Narita K. [Synthetic Study on Bicyclic Depsipeptides Containing an Intramolecular Disulfide Bond]. Yakugaku Zasshi 2022;142:917-26. [PMID: 36047217 DOI: 10.1248/yakushi.22-00091] [Reference Citation Analysis]
4 Sun Y, Hong JH, Ning Z, Pan D, Fu X, Lu X, Tan J. Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol 2022;13:932914. [DOI: 10.3389/fphar.2022.932914] [Reference Citation Analysis]
5 Chmielewska N, Wawer A, Osuch B, Maciejak P, Szyndler J. mTOR and HDAC2 are simultaneously activated during electrically induced kindling of seizures. Epilepsy Research 2022;185:106991. [DOI: 10.1016/j.eplepsyres.2022.106991] [Reference Citation Analysis]
6 Archibald LJ, Brown EA, Millard CJ, Watson PJ, Robertson NS, Wang S, Schwabe JWR, Jamieson AG. Hydroxamic Acid-Modified Peptide Library Provides Insights into the Molecular Basis for the Substrate Selectivity of HDAC Corepressor Complexes. ACS Chem Biol 2022. [PMID: 35973051 DOI: 10.1021/acschembio.2c00510] [Reference Citation Analysis]
7 Korkmaz IN, Özdemir H. Synthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents. Appl Biochem Biotechnol 2022. [PMID: 35917102 DOI: 10.1007/s12010-022-04107-z] [Reference Citation Analysis]
8 Suthar SK, Chundawat NS, Singh GP, Padrón JM, Jhala YK. Quinoxaline: A comprehension of current pharmacological advancement in medicinal chemistry. European Journal of Medicinal Chemistry Reports 2022;5:100040. [DOI: 10.1016/j.ejmcr.2022.100040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tinkov OV, Grigorev VY, Grigoreva LD, Osipov VN, Kolotaev AV, Khachatryan DS. QSAR analysis and experimental evaluation of new quinazoline-containing hydroxamic acids as histone deacetylase 6 inhibitors. SAR QSAR Environ Res 2022;:1-20. [PMID: 35786151 DOI: 10.1080/1062936X.2022.2092210] [Reference Citation Analysis]
10 Rahbari R, Rahimi K, Rasmi Y, Khadem-Ansari MH, Abdi M. miR-589-5p Inhibits Cell Proliferation by Targeting Histone Deacetylase 3 in Triple Negative Breast Cancer. Arch Med Res 2022;53:483-91. [PMID: 35840467 DOI: 10.1016/j.arcmed.2022.06.006] [Reference Citation Analysis]
11 Balbuena-rebolledo I, Rivera-antonio AM, Sixto-lópez Y, Correa-basurto J, Rosales-hernández MC, Mendieta-wejebe JE, Martínez-martínez FJ, Olivares-corichi IM, García-sánchez JR, Guevara-salazar JA, Bello M, Padilla-martínez II. Dihydropyrazole-Carbohydrazide Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6. Pharmaceuticals 2022;15:690. [DOI: 10.3390/ph15060690] [Reference Citation Analysis]
12 Rahbari R, Rasmi Y, Khadem-Ansari MH, Abdi M. The role of histone deacetylase 3 in breast cancer. Med Oncol 2022;39:84. [PMID: 35578147 DOI: 10.1007/s12032-022-01681-4] [Reference Citation Analysis]
13 Lemelle L, Moya-plana A, Dumont B, Fresneau B, Laprie A, Claude L, Deneuve S, Cordero C, Pierron G, Couloigner V, Bernard S, Cardoen L, Brisse HJ, Jehanno N, Metayer L, Fréneaux P, Helfre S, Kolb F, Thariat J, Réguerre Y, Orbach D. NUT carcinoma in children, adolescents and young adults. Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.01.015] [Reference Citation Analysis]
14 Adamczyk M, Wender-Ozegowska E, Kedzia M. Epigenetic Factors in Eutopic Endometrium in Women with Endometriosis and Infertility. Int J Mol Sci 2022;23:3804. [PMID: 35409163 DOI: 10.3390/ijms23073804] [Reference Citation Analysis]
15 Bui HTB, Nguyen PH, Pham QM, Tran HP, Tran DQ, Jung H, Hong QV, Nguyen QC, Nguyen QP, Le HT, Yang S. Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety. Molecules 2022;27:2204. [DOI: 10.3390/molecules27072204] [Reference Citation Analysis]
16 Kwak S, Park SH, Kim SH, Sung GJ, Song JH, Jeong JH, Kim H, Ha CH, Kim SW, Choi KC. miR-3189-targeted GLUT3 repression by HDAC2 knockdown inhibits glioblastoma tumorigenesis through regulating glucose metabolism and proliferation. J Exp Clin Cancer Res 2022;41:87. [PMID: 35260183 DOI: 10.1186/s13046-022-02305-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Essien EI, Hofer TP, Atkinson MJ, Anastasov N. Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres. Cells 2022;11:775. [DOI: 10.3390/cells11050775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Özel M, Başkol G, Başkol M, Güneş F, Uçar Ç, Doğru BN, Akalın H. SAHA induce hippo pathway in CCA cells without increasing cell proliferation. Mol Biol Rep 2022. [PMID: 35112301 DOI: 10.1007/s11033-022-07204-8] [Reference Citation Analysis]
19 Ruzic D, Djoković N, Srdić-rajić T, Echeverria C, Nikolic K, Santibanez JF. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. Pharmaceutics 2022;14:209. [DOI: 10.3390/pharmaceutics14010209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
20 Lu Y, Feng Y, Li Z, Li J, Zhang H, Hu X, Jiang W, Shi T, Wang Z. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression. Eur J Med Chem 2022;227:113908. [PMID: 34656900 DOI: 10.1016/j.ejmech.2021.113908] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Feng Y, Lu Y, Li J, Zhang H, Li Z, Feng H, Deng X, Liu D, Shi T, Jiang W, He Y, Zhang J, Wang Z. Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo. Eur J Med Chem 2022;227:113888. [PMID: 34628244 DOI: 10.1016/j.ejmech.2021.113888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
22 Baumann C, Zhang X, Zhu L, Fan Y, De La Fuente R. Changes in chromatin accessibility landscape and histone H3 core acetylation during valproic acid-induced differentiation of embryonic stem cells. Epigenetics Chromatin 2021;14:58. [PMID: 34955095 DOI: 10.1186/s13072-021-00432-5] [Reference Citation Analysis]
23 Fischer F, Alves Avelar LA, Murray L, Kurz T. Designing HDAC-PROTACs: lessons learned so far. Future Med Chem 2021. [PMID: 34951318 DOI: 10.4155/fmc-2021-0206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
24 Shi Y, Li Y, Yang K, Wei G, Huang A. Antimicrobial Peptide BCp12 Inhibits Staphylococcus aureus Growth by Altering Lysine Malonylation Levels in the Arginine Synthesis Pathway. J Agric Food Chem 2021. [PMID: 34942069 DOI: 10.1021/acs.jafc.1c05894] [Reference Citation Analysis]
25 Bass AKA, Nageeb EM, El-Zoghbi MS, Mohamed MFA, Badr M, Abuo-Rahma GEA. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. Bioorg Chem 2021;119:105564. [PMID: 34959179 DOI: 10.1016/j.bioorg.2021.105564] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Bhatia S, Yan Y, Ly M, Wells PG. Sex- and OGG1-dependent reversal of in utero ethanol-initiated changes in postnatal behaviour by neonatal treatment with the histone deacetylase inhibitor trichostatin A (TSA) in oxoguanine glycosylase 1 (Ogg1) knockout mice. Toxicol Lett 2021;356:121-31. [PMID: 34923047 DOI: 10.1016/j.toxlet.2021.12.010] [Reference Citation Analysis]
27 Cao D, Song Q, Li J, Jiang Y, Wang Z, Lu S. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer. Expert Rev Mol Med 2021;23:e21. [PMID: 34906271 DOI: 10.1017/erm.2021.26] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
28 Barman M, Kamble S, Roy S, Bhandari V, Singothu S, Dandasena D, Suresh A, Sharma P. Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors. Front Microbiol 2021;12:759817. [PMID: 34867888 DOI: 10.3389/fmicb.2021.759817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Pająk B, Siwiak-Niedbalska E, Jaśkiewicz A, Sołtyka M, Zieliński R, Domoradzki T, Fokt I, Skóra S, Priebe W. Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model. Biomedicines 2021;9:1749. [PMID: 34944565 DOI: 10.3390/biomedicines9121749] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Ibrahim TS, Malebari AM, Mohamed MFA. Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors. Pharmaceuticals (Basel) 2021;14:1177. [PMID: 34832959 DOI: 10.3390/ph14111177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Dewaker V, Srivastava PN, Verma S, Srivastava AK, Prabhakar YS. Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation. J Biomol Struct Dyn 2021;:1-24. [PMID: 34662251 DOI: 10.1080/07391102.2021.1989037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Jayanthi S, McCoy MT, Cadet JL. Epigenetic Regulatory Dynamics in Models of Methamphetamine-Use Disorder. Genes (Basel) 2021;12:1614. [PMID: 34681009 DOI: 10.3390/genes12101614] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Yang WB, Wu AC, Hsu TI, Liou JP, Lo WL, Chang KY, Chen PY, Kikkawa U, Yang ST, Kao TJ, Chen RM, Chang WC, Ko CY, Chuang JY. Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells. Cell Death Dis 2021;12:884. [PMID: 34584069 DOI: 10.1038/s41419-021-04182-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
34 Hafez DA, Hassanin IA, Teleb M, Khattab SN, Elkhodairy KA, Elzoghby AO. Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy. Nanomedicine (Lond) 2021;16:2305-25. [PMID: 34551585 DOI: 10.2217/nnm-2021-0196] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Upadhyay N, Tilekar K, Safuan S, Kumar AP, Schweipert M, Meyer-Almes FJ, C S R. Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks. RSC Med Chem 2021;12:1540-54. [PMID: 34671737 DOI: 10.1039/d1md00125f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Bauer I, Graessle S. Fungal Lysine Deacetylases in Virulence, Resistance, and Production of Small Bioactive Compounds. Genes (Basel) 2021;12:1470. [PMID: 34680865 DOI: 10.3390/genes12101470] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Upadhyay N, Tilekar K, Safuan S, Kumar AP, Schweipert M, Meyer-Almes FJ, Ramaa CS. Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis. Bioorg Chem 2021;116:105350. [PMID: 34547645 DOI: 10.1016/j.bioorg.2021.105350] [Reference Citation Analysis]
38 Khwaja S, Kumar K, Das R, Negi AS. Microtubule associated proteins as targets for anticancer drug development. Bioorg Chem 2021;116:105320. [PMID: 34492559 DOI: 10.1016/j.bioorg.2021.105320] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
39 Mehrpouri M, Pourbagheri-Sigaroodi A, Bashash D. The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. Int Immunopharmacol 2021;100:108114. [PMID: 34492531 DOI: 10.1016/j.intimp.2021.108114] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
40 Sirous H, Campiani G, Calderone V, Brogi S. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Comput Biol Med 2021;137:104808. [PMID: 34478925 DOI: 10.1016/j.compbiomed.2021.104808] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
41 Singh A, Patel VK, Rajak H. Appraisal of pyrrole as connecting unit in hydroxamic acid based histone deacetylase inhibitors: Synthesis, anticancer evaluation and molecular docking studies. Journal of Molecular Structure 2021;1240:130590. [DOI: 10.1016/j.molstruc.2021.130590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Bieszczad B, Garbicz D, Świtalska M, Dudek MK, Warszycki D, Wietrzyk J, Grzesiuk E, Mieczkowski A. Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues. Pharmaceuticals (Basel) 2021;14:851. [PMID: 34577551 DOI: 10.3390/ph14090851] [Reference Citation Analysis]
43 Dele-Oni DO, Christianson KE, Egri SB, Vaca Jacome AS, DeRuff KC, Mullahoo J, Sharma V, Davison D, Ko T, Bula M, Blanchard J, Young JZ, Litichevskiy L, Lu X, Lam D, Asiedu JK, Toder C, Officer A, Peckner R, MacCoss MJ, Tsai LH, Carr SA, Papanastasiou M, Jaffe JD. Proteomic profiling dataset of chemical perturbations in multiple biological backgrounds. Sci Data 2021;8:226. [PMID: 34433823 DOI: 10.1038/s41597-021-01008-4] [Reference Citation Analysis]
44 Sadova AA, Panteleev DY, Pavlova GV. Zooming in: PAGE-Northern Blot Helps to Analyze Anti-Sense Transcripts Originating from Human rIGS under Transcriptional Stress. Noncoding RNA 2021;7:50. [PMID: 34449671 DOI: 10.3390/ncrna7030050] [Reference Citation Analysis]
45 Hernández-Borja F, Mercado-Sánchez I, Alcaraz Y, García-Revilla MA, Villegas Gómez C, Ordaz-Rosado D, Santos-Martínez N, García-Becerra R, Vazquez MA. Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents. Daru 2021. [PMID: 34297326 DOI: 10.1007/s40199-021-00406-8] [Reference Citation Analysis]
46 Tantawy AH, Meng XG, Marzouk AA, Fouad A, Abdelazeem AH, Youssif BGM, Jiang H, Wang MQ. Structure-based design, synthesis, and biological evaluation of novel piperine-resveratrol hybrids as antiproliferative agents targeting SIRT-2. RSC Adv 2021;11:25738-51. [PMID: 35478872 DOI: 10.1039/d1ra04061h] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Khamidullina AI, Varlamova EA, Hammoud NA, Yastrebova MA, Bruter AV. Gene Transcription as a Therapeutic Target in Leukemia. Int J Mol Sci 2021;22:7340. [PMID: 34298959 DOI: 10.3390/ijms22147340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Peng Q, Li H, Deng Q, Liang L, Wang F, Lin Y, Yang L, Zhang Y, Yu X, Zhang L. Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer. J Colloid Interface Sci 2021;603:319-32. [PMID: 34186407 DOI: 10.1016/j.jcis.2021.06.066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
49 Richardson P. Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. Expert Opin Drug Discov 2021;:1-26. [PMID: 34074189 DOI: 10.1080/17460441.2021.1933427] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
50 Dewanjee S, Vallamkondu J, Kalra RS, Chakraborty P, Gangopadhyay M, Sahu R, Medala V, John A, Reddy PH, De Feo V, Kandimalla R. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus. Cells 2021;10:1340. [PMID: 34071497 DOI: 10.3390/cells10061340] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
51 Schnell AP, Kohrt S, Thoma-Kress AK. Latency Reversing Agents: Kick and Kill of HTLV-1? Int J Mol Sci 2021;22:5545. [PMID: 34073995 DOI: 10.3390/ijms22115545] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
52 Elmezayen AD, Al-Obaidi A, Yelekçi K. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment. J Mol Graph Model 2021;106:107937. [PMID: 34049193 DOI: 10.1016/j.jmgm.2021.107937] [Reference Citation Analysis]
53 Zalloum WA, Zalloum N. Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8. J Phys Chem B 2021;125:5321-37. [PMID: 33998791 DOI: 10.1021/acs.jpcb.1c01696] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Wu YW, Chao MW, Tu HJ, Chen LC, Hsu KC, Liou JP, Yang CR, Yen SC, HuangFu WC, Pan SL. A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo. Oncogenesis 2021;10:39. [PMID: 33986242 DOI: 10.1038/s41389-021-00331-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
55 Lipska K, Gumieniczek A, Pietraś R, Filip AA. HPLC-UV and GC-MS Methods for Determination of Chlorambucil and Valproic Acid in Plasma for Further Exploring a New Combined Therapy of Chronic Lymphocytic Leukemia. Molecules 2021;26:2903. [PMID: 34068372 DOI: 10.3390/molecules26102903] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
56 Shindo Y, Arai W, Konno T, Kohno T, Kodera Y, Chiba H, Miyajima M, Sakuma Y, Watanabe A, Kojima T. Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells. Histochem Cell Biol 2021;155:637-53. [PMID: 33974136 DOI: 10.1007/s00418-021-01966-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
57 Mirzaei R, Afaghi A, Babakhani S, Sohrabi MR, Hosseini-Fard SR, Babolhavaeji K, Khani Ali Akbari S, Yousefimashouf R, Karampoor S. Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother 2021;139:111619. [PMID: 33906079 DOI: 10.1016/j.biopha.2021.111619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
58 Ihezie SA, Mathew IE, McBride DW, Dienel A, Blackburn SL, Thankamani Pandit PK. Epigenetics in blood-brain barrier disruption. Fluids Barriers CNS 2021;18:17. [PMID: 33823899 DOI: 10.1186/s12987-021-00250-7] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
59 Davis FM, Tsoi LC, Melvin WJ, denDekker A, Wasikowski R, Joshi AD, Wolf S, Obi AT, Billi AC, Xing X, Audu C, Moore BB, Kunkel SL, Daugherty A, Lu HS, Gudjonsson JE, Gallagher KA. Inhibition of macrophage histone demethylase JMJD3 protects against abdominal aortic aneurysms. J Exp Med 2021;218:e20201839. [PMID: 33779682 DOI: 10.1084/jem.20201839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
60 Osipyan A, Chen D, Dekker FJ. Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation. Drug Discov Today 2021;26:1728-34. [PMID: 33746067 DOI: 10.1016/j.drudis.2021.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Zając A, Król SK, Rutkowski P, Czarnecka AM. Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype. Cancers (Basel) 2021;13:1317. [PMID: 33804155 DOI: 10.3390/cancers13061317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Stott AJ, Maillard MC, Beaumont V, Allcock D, Aziz O, Borchers AH, Blackaby W, Breccia P, Creighton-Gutteridge G, Haughan AF, Jarvis RE, Luckhurst CA, Matthews KL, McAllister G, Pollack S, Saville-Stones E, Van de Poël AJ, Vater HD, Vann J, Williams R, Yates D, Muñoz-Sanjuán I, Dominguez C. Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease. ACS Med Chem Lett 2021;12:380-8. [PMID: 33738065 DOI: 10.1021/acsmedchemlett.0c00532] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
63 Armstrong H, Bording-Jorgensen M, Wine E. The Multifaceted Roles of Diet, Microbes, and Metabolites in Cancer. Cancers (Basel) 2021;13:767. [PMID: 33673140 DOI: 10.3390/cancers13040767] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Takahashi Y, Hayakawa A, Sano R, Fukuda H, Harada M, Kubo R, Okawa T, Kominato Y. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19. Sci Rep 2021;11:3379. [PMID: 33564039 DOI: 10.1038/s41598-021-82970-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
65 Sinha S, Sharma S, Sharma A, Vora J, Shrivastava N. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis. Phytomedicine 2021;84:153492. [PMID: 33640782 DOI: 10.1016/j.phymed.2021.153492] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
66 Akbari E, Mousazadeh H, Sabet Z, Fattahi T, Dehnad A, Akbarzadeh A, Alizadeh E. Dual drug delivery of trapoxin A and methotrexate from biocompatible PLGA-PEG polymeric nanoparticles enhanced antitumor activity in breast cancer cell line. Journal of Drug Delivery Science and Technology 2021;61:102294. [DOI: 10.1016/j.jddst.2020.102294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
67 Ranjan K, Brandão F, Morais JAV, Muehlmann LA, Silva-Pereira I, Bocca AL, Matos LF, Poças-Fonseca MJ. The role of Cryptococcus neoformans histone deacetylase genes in the response to antifungal drugs, epigenetic modulators and to photodynamic therapy mediated by an aluminium phthalocyanine chloride nanoemulsion in vitro. J Photochem Photobiol B 2021;216:112131. [PMID: 33517071 DOI: 10.1016/j.jphotobiol.2021.112131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Lourenço de Freitas N, Deberaldini MG, Gomes D, Pavan AR, Sousa Â, Dos Santos JL, Soares CP. Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus. Front Cell Dev Biol 2020;8:592868. [PMID: 33634093 DOI: 10.3389/fcell.2020.592868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
69 Yang H, Chen L, Sun Q, Yao F, Muhammad S, Sun C. The role of HDAC11 in obesity-related metabolic disorders: A critical review. J Cell Physiol 2021;236:5582-91. [PMID: 33481312 DOI: 10.1002/jcp.30286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Yoo J, Jeon YH, Lee DH, Kim GW, Lee SW, Kim SY, Park J, Kwon SH. HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells. Oncol Lett 2021;21:201. [PMID: 33574940 DOI: 10.3892/ol.2021.12462] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
71 Bhagat SD, Chanchal A, Gujrati M, Banerjee A, Mishra RK, Srivastava A. Implantable HDAC-inhibiting chemotherapeutics derived from hydrophobic amino acids for localized anticancer therapy. Biomater Sci 2021;9:261-71. [PMID: 33196720 DOI: 10.1039/d0bm01417f] [Reference Citation Analysis]
72 Kobauri P, Szymanski W, Cao F, Thallmair S, Marrink SJ, Witte MD, Dekker FJ, Feringa BL. Biaryl sulfonamides as cisoid azosteres for photopharmacology. Chem Commun 2021;57:4126-9. [DOI: 10.1039/d1cc00950h] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Wang L, Zhang C, Hong Y, Li X, Li T, Gao A, Pan S, Liu B, Jin H, Cui D. Integrating Epigenetic Modulators in Nanofibers for Synergistic Gastric Cancer Therapy via Epigenetic Reprogramming. Nano Lett 2021;21:298-307. [PMID: 33356327 DOI: 10.1021/acs.nanolett.0c03665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
74 Zwergel C, Di Bello E, Fioravanti R, Conte M, Nebbioso A, Mazzone R, Brosch G, Mercurio C, Varasi M, Altucci L, Valente S, Mai A. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem 2021;16:989-99. [PMID: 33220015 DOI: 10.1002/cmdc.202000854] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
75 Mackwitz MKW, Hesping E, Eribez K, Schöler A, Antonova-Koch Y, Held J, Winzeler EA, Andrews KT, Hansen FK. Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity. Eur J Med Chem 2021;211:113065. [PMID: 33360801 DOI: 10.1016/j.ejmech.2020.113065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Gajendran B, Varier KM, Liu W, Wang C, Sample KM, Zacksenhaus E, Juiwei C, Huang L, Hao X, Ben-David Y. A C21-steroidal derivative suppresses T-cell lymphoma in mice by inhibiting SIRT3 via SAP18-SIN3. Commun Biol 2020;3:732. [PMID: 33273692 DOI: 10.1038/s42003-020-01458-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
77 Peng X, Sun Z, Kuang P, Chen J. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European Journal of Medicinal Chemistry 2020;208:112831. [DOI: 10.1016/j.ejmech.2020.112831] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
78 Pitsillou E, Liang J, Hung A, Karagiannis TC. The circadian machinery links metabolic disorders and depression: A review of pathways, proteins and potential pharmacological interventions. Life Sci 2021;265:118809. [PMID: 33249097 DOI: 10.1016/j.lfs.2020.118809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
79 Luo Y, Li H. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs). Int J Mol Sci 2020;21:E8828. [PMID: 33266366 DOI: 10.3390/ijms21228828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
80 Plotnikov A, Kozer N, Cohen G, Carvalho S, Duberstein S, Almog O, Solmesky LJ, Shurrush KA, Babaev I, Benjamin S, Gilad S, Kupervaser M, Levin Y, Gershovits M, Ben-Avraham D, Barr HM. PRMT1 inhibition induces differentiation of colon cancer cells. Sci Rep 2020;10:20030. [PMID: 33208761 DOI: 10.1038/s41598-020-77028-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
81 Biersack B, Polat S, Höpfner M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol 2020:S1044-579X(20)30223-6. [PMID: 33189849 DOI: 10.1016/j.semcancer.2020.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenetics 2020;12:169. [PMID: 33160401 DOI: 10.1186/s13148-020-00962-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
83 Kaur M, Loveleen, Kumar R. Inhibition of histone deacetylases, topoisomerases and epidermal growth factor receptor by metal-based anticancer agents: Design & synthetic strategies and their medicinal attributes. Bioorg Chem 2020;105:104396. [PMID: 33130345 DOI: 10.1016/j.bioorg.2020.104396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
84 Chen CC, Hsu CY, Lin HY, Zeng HQ, Cheng KH, Wu CW, Tsai EM, Hsieh TH. KRAS K104 modification affects the KRASG12D-GEF interaction and mediates cell growth and motility. Sci Rep 2020;10:17447. [PMID: 33060649 DOI: 10.1038/s41598-020-74463-5] [Reference Citation Analysis]
85 García-Costela M, Escudero-Feliú J, Puentes-Pardo JD, San Juán SM, Morales-Santana S, Ríos-Arrabal S, Carazo Á, León J. Circadian Genes as Therapeutic Targets in Pancreatic Cancer. Front Endocrinol (Lausanne) 2020;11:638. [PMID: 33042011 DOI: 10.3389/fendo.2020.00638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
86 Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M, Abuo-Rahma GEA. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem 2021;209:112904. [PMID: 33077264 DOI: 10.1016/j.ejmech.2020.112904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
87 Abosharaf HA, Diab T, Atlam FM, Mohamed TM. Osthole extracted from a citrus fruit that affects apoptosis on A549 cell line by histone deacetylasese inhibition (HDACs). Biotechnol Rep (Amst) 2020;28:e00531. [PMID: 33014717 DOI: 10.1016/j.btre.2020.e00531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
88 Hontecillas-Prieto L, Flores-Campos R, Silver A, de Álava E, Hajji N, García-Domínguez DJ. Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. Front Genet 2020;11:578011. [PMID: 33024443 DOI: 10.3389/fgene.2020.578011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
89 Lipska K, Gumieniczek A, Filip AA. Anticonvulsant valproic acid and other short-chain fatty acids as novel anticancer therapeutics: Possibilities and challenges. Acta Pharm 2020;70:291-301. [PMID: 32074065 DOI: 10.2478/acph-2020-0021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
90 Hyndman KA, Speed JS, Mendoza LD, Allan JM, Colson J, Sedaka R, Jin C, Jung HJ, El-Dahr S, Pollock DM, Pollock JS. Fluid-electrolyte homeostasis requires histone deacetylase function. JCI Insight 2020;5:137792. [PMID: 32673289 DOI: 10.1172/jci.insight.137792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
91 Chen CY, Fang JY, Chen CC, Chuang WY, Leu YL, Ueng SH, Wei LS, Cheng SF, Hsueh C, Wang TH. 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression. Front Oncol 2020;10:1319. [PMID: 32850418 DOI: 10.3389/fonc.2020.01319] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Curr Med Chem 2020;27:2449-93. [PMID: 30332940 DOI: 10.2174/0929867325666181016163110] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
93 Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs 2020;29:525-36. [PMID: 32693648 DOI: 10.1080/13543784.2020.1761323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
94 Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, Ding Y, Wang Y. The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res 2020;39:138. [PMID: 32682428 DOI: 10.1186/s13046-020-01643-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
95 Aydin C, Kalkan R. Cancer Treatment: An Epigenetic View. Glob Med Genet 2020;7:3-7. [PMID: 32879917 DOI: 10.1055/s-0040-1713610] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
96 Garrido González FP, Mancilla Percino T. Synthesis, docking study and inhibitory activity of 2,6-diketopiperazines derived from α-amino acids on HDAC8. Bioorg Chem 2020;102:104080. [PMID: 32683182 DOI: 10.1016/j.bioorg.2020.104080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
97 Friedrich A, Assmann AS, Schumacher L, Stuijvenberg JV, Kassack MU, Schulz WA, Roos WP, Hansen FK, Pflieger M, Kurz T, Fritz G. In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). Int J Mol Sci 2020;21:E4747. [PMID: 32635356 DOI: 10.3390/ijms21134747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
98 Wu Y, Sun Y, Dong X, Chen J, Wang Z, Chen J, Dong G. The Synergism of PGN, LTA and LPS in Inducing Transcriptome Changes, Inflammatory Responses and a Decrease in Lactation as Well as the Associated Epigenetic Mechanisms in Bovine Mammary Epithelial Cells. Toxins (Basel) 2020;12:E387. [PMID: 32545333 DOI: 10.3390/toxins12060387] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
99 Kulka LAM, Fangmann PV, Panfilova D, Olzscha H. Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Front Cell Dev Biol 2020;8:425. [PMID: 32582706 DOI: 10.3389/fcell.2020.00425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
100 Zhang M, Ying JB, Wang SS, He D, Zhu H, Zhang C, Tang L, Lin R, Zhang Y. Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group. J Cell Biochem 2020;121:3162-72. [DOI: 10.1002/jcb.29583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
101 Pourrajab F, Zare-Khormizi MR, Hekmatimoghaddam S, Hashemi AS. Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia. J Exp Pharmacol 2020;12:107-28. [PMID: 32581600 DOI: 10.2147/JEP.S254334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
102 Sharifi-Rad M, Epifano F, Fiorito S, Álvarez-Suarez JM. Phytochemical Analysis and Biological Investigation of Nepeta juncea Benth. Different Extracts. Plants (Basel) 2020;9:E646. [PMID: 32438667 DOI: 10.3390/plants9050646] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
103 Upadhyay N, Tilekar K, Jänsch N, Schweipert M, Hess JD, Henze Macias L, Mrowka P, Aguilera RJ, Choe JY, Meyer-Almes FJ, Ramaa CS. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorg Chem 2020;100:103934. [PMID: 32446120 DOI: 10.1016/j.bioorg.2020.103934] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
104 Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes (Basel) 2020;11:E556. [PMID: 32429325 DOI: 10.3390/genes11050556] [Cited by in Crossref: 39] [Cited by in F6Publishing: 73] [Article Influence: 19.5] [Reference Citation Analysis]
105 Singhal S, Pathak M, Agrawala PK, Ojha H. Design and in silico screening of aryl allyl mercaptan analogs as potential histone deacetylases (HDAC) inhibitors. Heliyon 2020;6:e03517. [PMID: 32426531 DOI: 10.1016/j.heliyon.2020.e03517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Tng J, Lim J, Wu K, Lucke AJ, Xu W, Reid RC, Fairlie DP. Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation. J Med Chem 2020;63:5956-71. [DOI: 10.1021/acs.jmedchem.0c00230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
107 Shaik B, Zafar T, Gupta SP. Recent Studies on HDAC Inhibitors Acting against Prostate Cancer. CEI 2020;16:74-89. [DOI: 10.2174/1573408016666200402092557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
108 Singh AN, Sharma N. Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer. Protein J. 2019;. [PMID: 30993446 DOI: 10.1007/s10930-019-09832-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
109 Yun F, Cheng C, Ullah S, Yuan Q. Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer. Eur J Med Chem 2020;198:112322. [PMID: 32361064 DOI: 10.1016/j.ejmech.2020.112322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
110 Dompe C, Janowicz K, Hutchings G, Moncrieff L, Jankowski M, Nawrocki MJ, Józkowiak M, Mozdziak P, Petitte J, Shibli JA, Dyszkiewicz-Konwińska M, Bruska M, Piotrowska-Kempisty H, Kempisty B, Nowicki M. Epigenetic Research in Stem Cell Bioengineering-Anti-Cancer Therapy, Regenerative and Reconstructive Medicine in Human Clinical Trials. Cancers (Basel) 2020;12:E1016. [PMID: 32326172 DOI: 10.3390/cancers12041016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
111 Liu J, Zhou J, He F, Gao L, Wen Y, Gao L, Wang P, Kang D, Hu L. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening. European Journal of Medicinal Chemistry 2020;192:112189. [DOI: 10.1016/j.ejmech.2020.112189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
112 Sarkar R, Banerjee S, Amin SA, Adhikari N, Jha T. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review. European Journal of Medicinal Chemistry 2020;192:112171. [DOI: 10.1016/j.ejmech.2020.112171] [Cited by in Crossref: 13] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
113 Ibrahim TS, Sheha TA, Abo-Dya NE, AlAwadh MA, Alhakamy NA, Abdel-Samii ZK, Panda SS, Abuo-Rahma GEA, Mohamed MFA. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity. Bioorg Chem 2020;99:103797. [PMID: 32247939 DOI: 10.1016/j.bioorg.2020.103797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
114 Osipov VN, Khachatryan DS, Balaev AN. Biologically active quinazoline-based hydroxamic acids. Med Chem Res 2020;29:831-45. [DOI: 10.1007/s00044-020-02530-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Liow E, Tran B. Precision oncology in urothelial cancer. ESMO Open 2020;5:e000616. [PMID: 32132102 DOI: 10.1136/esmoopen-2019-000616] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Amin SA, Adhikari N, Jha T. Exploration of histone deacetylase 8 inhibitors through classification QSAR study: Part II. Journal of Molecular Structure 2020;1204:127529. [DOI: 10.1016/j.molstruc.2019.127529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
117 Wu B, Fathi S, Mortley S, Mohiuddin M, Jang YC, Oyelere AK. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity. Bioorganic & Medicinal Chemistry 2020;28:115345. [DOI: 10.1016/j.bmc.2020.115345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
118 Chen CY, Chen CC, Chuang WY, Leu YL, Ueng SH, Hsueh C, Yeh CT, Wang TH. Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells. Front Oncol 2020;10:216. [PMID: 32158695 DOI: 10.3389/fonc.2020.00216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
119 Sultana F, Manasa KL, Shaik SP, Bonam SR, Kamal A. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Curr Med Chem 2019;26:7212-80. [PMID: 29852860 DOI: 10.2174/0929867325666180530094120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
120 Brown JA. Patent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi). Pharm Pat Anal 2020;9:17-28. [PMID: 32008421 DOI: 10.4155/ppa-2019-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Gurbani SS, Yoon Y, Weinberg BD, Salgado E, Press RH, Cordova JS, Ramesh KK, Liang Z, Velazquez Vega J, Voloschin A, Olson JJ, Schreibmann E, Shim H, Shu HG. Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI. Tomography 2019;5:53-60. [PMID: 30854442 DOI: 10.18383/j.tom.2018.00031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
122 Khalil NA, Ahmed EM, Zaher AF, El-zoghbi MS, Sobh EA. Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors. European Journal of Medicinal Chemistry 2020;187:111926. [DOI: 10.1016/j.ejmech.2019.111926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
123 Liu S, Hu Z, Zhang Q, Zhu Q, Chen Y, Lu W. Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and Vorinostat with in Vitro Hydrolysis and Anticancer Effects. ACS Omega 2020;5:350-7. [PMID: 31956782 DOI: 10.1021/acsomega.9b02786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
124 Tago T, Toyohara J, Ishii K. Radiosynthesis and preliminary evaluation of an 18 F-labeled tubastatin A analog for PET imaging of histone deacetylase 6. J Label Compd Radiopharm 2020;63:85-95. [DOI: 10.1002/jlcr.3823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
125 Kashyap K, Kakkar R. Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study. J Biomol Struct Dyn 2021;39:502-17. [PMID: 31900046 DOI: 10.1080/07391102.2019.1711191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
126 Jacques C, Lavaud M, Georges S, Tesfaye R, Baud’huin M, Lamoureux F, Ory B. BET bromodomains’ functions in bone-related pathologies. Epigenomics 2020;12:127-44. [DOI: 10.2217/epi-2019-0172] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
127 V Stoddard S, Dodson K, Adams K, L Watkins D. In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity. Int J Mol Sci 2019;21:E219. [PMID: 31905609 DOI: 10.3390/ijms21010219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
128 Green AL, DeSisto J, Flannery P, Lemma R, Knox A, Lemieux M, Sanford B, O'Rourke R, Ramkissoon S, Jones K, Perry J, Hui X, Moroze E, Balakrishnan I, O'Neill AF, Dunn K, DeRyckere D, Danis E, Safadi A, Gilani A, Hubbell-Engler B, Nuss Z, Levy JMM, Serkova N, Venkataraman S, Graham DK, Foreman N, Ligon K, Jones K, Kung AL, Vibhakar R. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene 2020;39:2305-27. [PMID: 31844250 DOI: 10.1038/s41388-019-1125-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
129 Shi X, Gong L, Liu Y, Hou K, Fan Y, Li C, Wen T, Qu X, Che X. 4-phenylbutyric acid promotes migration of gastric cancer cells by histone deacetylase inhibition-mediated IL-8 upregulation. Epigenetics 2020;15:632-45. [PMID: 31814524 DOI: 10.1080/15592294.2019.1700032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
130 Zhang C, Guo S, Zhong Q, Zhang Q, Hossain A, Zheng S, Wang G. Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability. Pharmaceuticals (Basel) 2019;12:E180. [PMID: 31817969 DOI: 10.3390/ph12040180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenetics 2019;11:174. [PMID: 31791394 DOI: 10.1186/s13148-019-0776-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 124] [Article Influence: 35.0] [Reference Citation Analysis]
132 Bai Y, Ahmad D, Wang T, Cui G, Li W. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer. Curr Top Med Chem 2019;19:995-1004. [PMID: 30686256 DOI: 10.2174/1568026619666190125145110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
133 Kolotaev AV, Matevosyan KR, Osipov VN, Khachatryan DS. Synthesis of new quinazoline-containing hydroxamic acids as potential HDAC/VEGFR inhibitors. Unusual rearrangements with pyrrolidone ring opening and dehydration of 3-N-hydroxyquinazoline fragment containing tetracycles. Tetrahedron Letters 2019;60:151315. [DOI: 10.1016/j.tetlet.2019.151315] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
134 Neiband MS, Benvidi A, Mani-varnosfaderani A. Development of classification models for identification of important structural features of isoform-selective histone deacetylase inhibitors (class I). Mol Divers 2020;24:1077-94. [DOI: 10.1007/s11030-019-10013-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
135 Krieger V, Hamacher A, Cao F, Stenzel K, Gertzen CGW, Schäker-hübner L, Kurz T, Gohlke H, Dekker FJ, Kassack MU, Hansen FK. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties. J Med Chem 2019;62:11260-79. [DOI: 10.1021/acs.jmedchem.9b01489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
136 San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC Inhibitors in Acute Myeloid Leukemia. Cancers (Basel) 2019;11:E1794. [PMID: 31739588 DOI: 10.3390/cancers11111794] [Cited by in Crossref: 40] [Cited by in F6Publishing: 57] [Article Influence: 13.3] [Reference Citation Analysis]
137 James N, Shanthi V, Ramanathan K. Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors. Appl Biochem Biotechnol 2020;190:1127-46. [PMID: 31712989 DOI: 10.1007/s12010-019-03156-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
138 Zhang JH, Mottamal M, Jin HS, Guo S, Gu Y, Wang G, Zhao LM. Design, synthesis and evaluation of belinostat analogs as histone deacetylase inhibitors. Future Med Chem 2019;11:2765-78. [PMID: 31702394 DOI: 10.4155/fmc-2018-0587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Sanaei M, Kavoosi F. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers. Adv Biomed Res 2019;8:63. [PMID: 31737580 DOI: 10.4103/abr.abr_142_19] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 11.7] [Reference Citation Analysis]
140 El-Naggar AM, Somasekharan SP, Wang Y, Cheng H, Negri GL, Pan M, Wang XQ, Delaidelli A, Rafn B, Cran J, Zhang F, Zhang H, Colborne S, Gleave M, Mandinova A, Kedersha N, Hughes CS, Surdez D, Delattre O, Wang Y, Huntsman DG, Morin GB, Sorensen PH. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep 2019;20:e48375. [PMID: 31668005 DOI: 10.15252/embr.201948375] [Cited by in Crossref: 23] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
141 Zhao LM, Zhang JH. Histone Deacetylase Inhibitors in Tumor Immunotherapy. Curr Med Chem 2019;26:2990-3008. [PMID: 28762309 DOI: 10.2174/0929867324666170801102124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
142 Freese K, Seitz T, Dietrich P, Lee SML, Thasler WE, Bosserhoff A, Hellerbrand C. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro. Cancers (Basel) 2019;11:E1587. [PMID: 31635225 DOI: 10.3390/cancers11101587] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
143 Mehdipour P, Murphy T, De Carvalho DD. The role of DNA-demethylating agents in cancer therapy. Pharmacol Ther 2020;205:107416. [PMID: 31626871 DOI: 10.1016/j.pharmthera.2019.107416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
144 Autin P, Blanquart C, Fradin D. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers (Basel) 2019;11:E1530. [PMID: 31658720 DOI: 10.3390/cancers11101530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
145 Raudszus R, Nowotny R, Gertzen CG, Schöler A, Krizsan A, Gockel I, Kalwa H, Gohlke H, Thieme R, Hansen FK. Fluorescent analogs of peptoid-based HDAC inhibitors: Synthesis, biological activity and cellular uptake kinetics. Bioorganic & Medicinal Chemistry 2019;27:115039. [DOI: 10.1016/j.bmc.2019.07.055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
146 Trivedi P, Adhikari N, Amin SA, Bobde Y, Ganesh R, Jha T, Ghosh B. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity. European Journal of Pharmaceutical Sciences 2019;138:105046. [DOI: 10.1016/j.ejps.2019.105046] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
147 Peyvandipour A, Saberian N, Shafi A, Donato M, Draghici S. A novel computational approach for drug repurposing using systems biology. Bioinformatics 2018;34:2817-25. [PMID: 29534151 DOI: 10.1093/bioinformatics/bty133] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 14.3] [Reference Citation Analysis]
148 Jászai J, Schmidt MHH. Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells 2019;8:E1102. [PMID: 31540455 DOI: 10.3390/cells8091102] [Cited by in Crossref: 56] [Cited by in F6Publishing: 74] [Article Influence: 18.7] [Reference Citation Analysis]
149 Guo W, Stoklund Dittlau K, Van Den Bosch L. Axonal transport defects and neurodegeneration: Molecular mechanisms and therapeutic implications. Semin Cell Dev Biol 2020;99:133-50. [PMID: 31542222 DOI: 10.1016/j.semcdb.2019.07.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
150 Erdeljac N, Bussmann K, Schöler A, Hansen FK, Gilmour R. Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE. ACS Med Chem Lett 2019;10:1336-40. [PMID: 31531206 DOI: 10.1021/acsmedchemlett.9b00287] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
151 Zwinderman MRH, de Weerd S, Dekker FJ. Targeting HDAC Complexes in Asthma and COPD. Epigenomes 2019;3:19. [DOI: 10.3390/epigenomes3030019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
152 Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Epigenetic Metalloenzymes. Curr Med Chem 2019;26:2748-85. [PMID: 29984644 DOI: 10.2174/0929867325666180706105903] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Sanaei M, Kavoosi F. Effect of 5-Aza-2'-Deoxycytidine in Comparison to Valproic Acid and Trichostatin A on Histone Deacetylase 1, DNA Methyltransferase 1, and CIP/KIP Family (p21, p27, and p57) Genes Expression, Cell Growth Inhibition, and Apoptosis Induction in Colon Cancer SW480 Cell Line. Adv Biomed Res 2019;8:52. [PMID: 31516890 DOI: 10.4103/abr.abr_91_19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
154 Sinha S, Patel S, Athar M, Vora J, Chhabria MT, Jha PC, Shrivastava N. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study. Int J Biol Macromol 2019;140:454-68. [PMID: 31404596 DOI: 10.1016/j.ijbiomac.2019.08.061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
155 Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: Promising agents for breast cancer treatment. Bioorg Chem 2019;91:103184. [PMID: 31408831 DOI: 10.1016/j.bioorg.2019.103184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
156 Gupta R, Bhatt LK, Momin M. Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1. Toxicology and Applied Pharmacology 2019;377:114631. [DOI: 10.1016/j.taap.2019.114631] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
157 Alam MA. Methods for Hydroxamic Acid Synthesis. Curr Org Chem 2019;23:978-93. [PMID: 32565717 DOI: 10.2174/1385272823666190424142821] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
158 Mohamed MFA, Youssif BGM, Shaykoon MSA, Abdelrahman MH, Elsadek BEM, Aboraia AS, Abuo-Rahma GEA. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors. Bioorg Chem 2019;91:103127. [PMID: 31374527 DOI: 10.1016/j.bioorg.2019.103127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
159 Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov 2019;18:609-28. [PMID: 31273347 DOI: 10.1038/s41573-019-0030-7] [Cited by in Crossref: 141] [Cited by in F6Publishing: 182] [Article Influence: 47.0] [Reference Citation Analysis]
160 Zong X, Nephew KP. Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. Cancers (Basel) 2019;11:E934. [PMID: 31277278 DOI: 10.3390/cancers11070934] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
161 Moertl S, Payer S, Kell R, Winkler K, Anastasov N, Atkinson MJ. Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells. Int J Mol Sci 2019;20:E3259. [PMID: 31269745 DOI: 10.3390/ijms20133259] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
162 Elmallah MIY, Micheau O. Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. Cancers (Basel) 2019;11:E850. [PMID: 31248188 DOI: 10.3390/cancers11060850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
163 Bouchet S, Linot C, Ruzic D, Agbaba D, Fouchaq B, Roche J, Nikolic K, Blanquart C, Bertrand P. Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. ACS Med Chem Lett 2019;10:863-8. [PMID: 31223439 DOI: 10.1021/acsmedchemlett.8b00440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
164 Crisci S, Di Francia R, Mele S, Vitale P, Ronga G, De Filippi R, Berretta M, Rossi P, Pinto A. Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. Front Oncol 2019;9:443. [PMID: 31214498 DOI: 10.3389/fonc.2019.00443] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
165 Hsieh Y, Tu H, Pan S, Liou J, Yang C. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2019;1866:992-1003. [DOI: 10.1016/j.bbamcr.2019.03.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
166 Mansouri N, Alivand MR, Bayat S, Khaniani MS, Derakhshan SM. The hopeful anticancer role of oleuropein in breast cancer through histone deacetylase modulation. J Cell Biochem 2019;120:17042-9. [PMID: 31119806 DOI: 10.1002/jcb.28965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
167 Hamam HJ, Palaniyar N. Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis. Biomolecules 2019;9:E184. [PMID: 31083537 DOI: 10.3390/biom9050184] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
168 Banerjee S, Adhikari N, Amin SA, Jha T. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study. J Biomol Struct Dyn 2020;38:1551-64. [PMID: 31074329 DOI: 10.1080/07391102.2019.1617782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
169 Gezici S, Şekeroğlu N. Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents. ACAMC 2019;19:101-11. [DOI: 10.2174/1871520619666181224121004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 71] [Article Influence: 15.0] [Reference Citation Analysis]
170 Pineda Molina C, Hussey GS, Eriksson J, Shulock MA, Cárdenas Bonilla LL, Giglio RM, Gandhi RM, Sicari BM, Wang D, Londono R, Faulk DM, Turner NJ, Badylak SF. 4-Hydroxybutyrate Promotes Endogenous Antimicrobial Peptide Expression in Macrophages. Tissue Engineering Part A 2019;25:693-706. [DOI: 10.1089/ten.tea.2018.0377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
171 Li Y, Wang F, Chen X, Wang J, Zhao Y, Li Y, He B. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. Curr Top Med Chem 2019;19:223-41. [PMID: 30674261 DOI: 10.2174/1568026619666190122144949] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
172 Jian X, Qu L, Wang Y, Zou Q, Zhao Q, Chen S, Gao X, Chen H, He C. Trichostatin A‑induced miR‑30a‑5p regulates apoptosis and proliferation of keloid fibroblasts via targeting BCL2. Mol Med Rep 2019;19:5251-62. [PMID: 31059100 DOI: 10.3892/mmr.2019.10185] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
173 Mahindra A, Millard CJ, Black I, Archibald LJ, Schwabe JWR, Jamieson AG. Synthesis of HDAC Substrate Peptidomimetic Inhibitors Using Fmoc Amino Acids Incorporating Zinc-Binding Groups. Org Lett 2019;21:3178-82. [PMID: 30998366 DOI: 10.1021/acs.orglett.9b00885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
174 Hammond N, Munkacsi AB, Sturley SL. The complexity of a monogenic neurodegenerative disease: More than two decades of therapeutic driven research into Niemann-Pick type C disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019;1864:1109-23. [PMID: 31002946 DOI: 10.1016/j.bbalip.2019.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
175 Uma K, Lalithamba HS, Chandramohan V, Lingaraju K. A Facile Synthesis of Hydroxamic Acids of N α -Protected Amino Acids Employing BDMS, a Study of Their Molecular Docking and Their Antibacterial Activities. Organic Preparations and Procedures International 2019;51:161-74. [DOI: 10.1080/00304948.2019.1579039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Bridgeman S, Northrop W, Ellison G, Sabapathy T, Melton PE, Newsholme P, Mamotte CDS. Statins Do Not Directly Inhibit the Activity of Major Epigenetic Modifying Enzymes. Cancers (Basel) 2019;11:E516. [PMID: 30974899 DOI: 10.3390/cancers11040516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
177 Xiong C, Guan Y, Zhou X, Liu L, Zhuang MA, Zhang W, Zhang Y, Masucci MV, Bayliss G, Zhao TC, Zhuang S. Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis. FASEB J 2019;33:8249-62. [PMID: 30951378 DOI: 10.1096/fj.201801067RR] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
178 Liu J, Zhu Y, He Y, Zhu H, Gao Y, Li Z, Zhu J, Sun X, Fang F, Wen H, Li W. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. J Biomol Struct Dyn 2020;38:533-47. [PMID: 30938574 DOI: 10.1080/07391102.2019.1590241] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
179 Jia R, Sun P, Zhang Y, Ge Y, Yu N. Minor structural modifications to Pracinostat produce big changes in its biological responses. Chem Biol Drug Des 2019;94:1488-93. [PMID: 30932330 DOI: 10.1111/cbdd.13527] [Reference Citation Analysis]
180 Han M, Jia L, Lv W, Wang L, Cui W. Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors. Front Oncol 2019;9:194. [PMID: 30984620 DOI: 10.3389/fonc.2019.00194] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 9.7] [Reference Citation Analysis]
181 Yannai S, Zonszain J, Donyo M, Ast G. Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients. PLoS One 2019;14:e0211602. [PMID: 30889183 DOI: 10.1371/journal.pone.0211602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
182 Yoon S, Kang G, Eom GH. HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases. Int J Mol Sci 2019;20:E1329. [PMID: 30884785 DOI: 10.3390/ijms20061329] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
183 Giannopoulou AF, Velentzas AD, Konstantakou EG, Avgeris M, Katarachia SA, Papandreou NC, Kalavros NI, Mpakou VE, Iconomidou V, Anastasiadou E, Kostakis IK, Papassideri IS, Voutsinas GE, Scorilas A, Stravopodis DJ. Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. Int J Mol Sci 2019;20:E1291. [PMID: 30875794 DOI: 10.3390/ijms20061291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
184 Patel P, Patel VK, Singh A, Jawaid T, Kamal M, Rajak H. Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies. CAD 2019;15:145-66. [DOI: 10.2174/1573409914666180502113135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Gatla HR, Muniraj N, Thevkar P, Yavvari S, Sukhavasi S, Makena MR. Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases. Int J Mol Sci 2019;20:E1110. [PMID: 30841513 DOI: 10.3390/ijms20051110] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
186 Laws MT, Bonomi RE, Kamal S, Gelovani DJ, Llaniguez J, Potukutchi S, Lu X, Mangner T, Gelovani JG. Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA. Sci Rep 2019;9:3595. [PMID: 30837601 DOI: 10.1038/s41598-019-40054-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
187 Lee DH, Kim GW, Kwon SH. The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Mol Carcinog 2019;58:944-56. [PMID: 30693983 DOI: 10.1002/mc.22983] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
188 Vaca HR, Celentano AM, Macchiaroli N, Kamenetzky L, Camicia F, Rosenzvit MC. Histone deacetylase enzymes as potential drug targets of Neglected Tropical Diseases caused by cestodes. Int J Parasitol Drugs Drug Resist 2019;9:120-32. [PMID: 30897528 DOI: 10.1016/j.ijpddr.2019.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
189 Mackwitz MKW, Hesping E, Antonova-Koch Y, Diedrich D, Woldearegai TG, Skinner-Adams T, Clarke M, Schöler A, Limbach L, Kurz T, Winzeler EA, Held J, Andrews KT, Hansen FK. Structure-Activity and Structure-Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity. ChemMedChem 2019;14:912-26. [PMID: 30664827 DOI: 10.1002/cmdc.201800808] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
190 Ishola AA, Adewole KE. Phytosterols and triterpenes from Morinda lucida Benth. exhibit binding tendency against class I HDAC and HDAC7 isoforms. Mol Biol Rep 2019;46:2307-25. [PMID: 30771146 DOI: 10.1007/s11033-019-04689-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
191 Dahbash M, Sella R, Megiddo-Barnir E, Nisgav Y, Tarasenko N, Weinberger D, Rephaeli A, Livnat T. The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model. Int J Mol Sci 2019;20:E714. [PMID: 30736437 DOI: 10.3390/ijms20030714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
192 Zhang Q, Wang S, Chen J, Yu Z. Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. Int J Med Sci 2019;16:424-42. [PMID: 30911277 DOI: 10.7150/ijms.30154] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
193 Sharma M, Jha P, Verma P, Chopra M. Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors. Chem Biol Drug Des 2019;93:910-25. [PMID: 30667160 DOI: 10.1111/cbdd.13488] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
194 Hamam HJ, Khan MA, Palaniyar N. Histone Acetylation Promotes Neutrophil Extracellular Trap Formation. Biomolecules 2019;9:E32. [PMID: 30669408 DOI: 10.3390/biom9010032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
195 Hieu DT, Anh DT, Hai PT, Thuan NT, Huong LT, Park EJ, Young Ji A, Soon Kang J, Phuong Dung PT, Han SB, Nam NH. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Chem Biodivers 2019;16:e1800502. [PMID: 30653817 DOI: 10.1002/cbdv.201800502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
196 Schmitt F, Gosch LC, Dittmer A, Rothemund M, Mueller T, Schobert R, Biersack B, Volkamer A, Höpfner M. Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure⁻Activity Relations of New Inhibitors of HDAC and/or Tubulin Function. Int J Mol Sci 2019;20:E383. [PMID: 30658435 DOI: 10.3390/ijms20020383] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
197 Gawandi SJ, Desai VG, Shingade SG. Design, synthesis, and biological evaluation of 1,3,5-trisubstituted pyrazoles as tyrosine kinase inhibitors. Med Chem Res 2019;28:267-78. [DOI: 10.1007/s00044-018-2282-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
198 Bayat S, Mansoori Derakhshan S, Mansoori Derakhshan N, Shekari Khaniani M, Alivand MR. Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells. J Cell Biochem 2019;120:9172-80. [PMID: 30618185 DOI: 10.1002/jcb.28193] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
199 Lu P, Yan M, He L, Li J, Ji Y, Ji J. Crosstalk between Epigenetic Modulations in Valproic Acid Deactivated Hepatic Stellate Cells: An Integrated Protein and miRNA Profiling Study. Int J Biol Sci. 2019;15:93-104. [PMID: 30662350 DOI: 10.7150/ijbs.28642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
200 Bouchut A, Rotili D, Pierrot C, Valente S, Lafitte S, Schultz J, Hoglund U, Mazzone R, Lucidi A, Fabrizi G, Pechalrieu D, Arimondo PB, Skinner-adams TS, Chua MJ, Andrews KT, Mai A, Khalife J. Identification of novel quinazoline derivatives as potent antiplasmodial agents. European Journal of Medicinal Chemistry 2019;161:277-91. [DOI: 10.1016/j.ejmech.2018.10.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
201 Yadav R, Mishra P, Yadav D. Histone Deacetylase Inhibitors: A Prospect in Drug Discovery. Turk J Pharm Sci 2019;16:101-14. [PMID: 32454703 DOI: 10.4274/tjps.75047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
202 Hillson O, Gonzalez S, Rallis C. Prospects of Pharmacological Interventions to Organismal Aging. Biomolecular Concepts 2018;9:200-15. [DOI: 10.1515/bmc-2018-0018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
203 Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer 2019;125:533-40. [PMID: 30570744 DOI: 10.1002/cncr.31817] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
204 Banerjee S, Adhikari N, Amin SA, Jha T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. Eur J Med Chem 2019;164:214-40. [PMID: 30594678 DOI: 10.1016/j.ejmech.2018.12.039] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
205 Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM. HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI. NMR Biomed 2019;32:e4044. [PMID: 30561869 DOI: 10.1002/nbm.4044] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
206 Lopes‐coelho F, Silva F, Hipólito A, Cardoso BA, Serpa J. Acetylation drives hepatocyte nuclear factor 1β stability by blocking proteasome‐mediated degradation. J Cell Biochem 2019;120:9337-44. [DOI: 10.1002/jcb.28209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
207 Tun N, Shibata Y, Soe MT, Htun MW, Koji T. Histone deacetylase inhibitors suppress transdifferentiation of gonadotrophs to prolactin cells and proliferation of prolactin cells induced by diethylstilbestrol in male mouse pituitary. Histochem Cell Biol 2019;151:291-303. [DOI: 10.1007/s00418-018-1760-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
208 Xu S, Kamato D, Little PJ, Nakagawa S, Pelisek J, Jin ZG. Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics. Pharmacol Ther 2019;196:15-43. [PMID: 30439455 DOI: 10.1016/j.pharmthera.2018.11.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 64] [Article Influence: 10.0] [Reference Citation Analysis]
209 Uba AI, Yelekçi K. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6. Comput Biol Chem 2018;77:318-30. [PMID: 30463049 DOI: 10.1016/j.compbiolchem.2018.10.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
210 Trivedi P, Adhikari N, Amin SA, Jha T, Ghosh B. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects. European Journal of Pharmaceutical Sciences 2018;124:165-81. [DOI: 10.1016/j.ejps.2018.08.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
211 Krajewski D, Kaczenski E, Rovatti J, Polukort S, Thompson C, Dollard C, Ser-Dolansky J, Schneider SS, Kinney SRM, Mathias CB. Epigenetic Regulation via Altered Histone Acetylation Results in Suppression of Mast Cell Function and Mast Cell-Mediated Food Allergic Responses. Front Immunol 2018;9:2414. [PMID: 30405614 DOI: 10.3389/fimmu.2018.02414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
212 Al-Keilani MS, Alzoubi KH, Jaradat SA. The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells. Clin Pharmacol 2018;10:135-40. [PMID: 30349406 DOI: 10.2147/CPAA.S174074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
213 Rompicharla SVK, Trivedi P, Kumari P, Muddineti OS, Theegalapalli S, Ghosh B, Biswas S. Evaluation of Anti-Tumor Efficacy of Vorinostat Encapsulated Self-Assembled Polymeric Micelles in Solid Tumors. AAPS PharmSciTech 2018;19:3141-51. [PMID: 30132129 DOI: 10.1208/s12249-018-1149-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
214 Temian DC, Pop LA, Irimie AI, Berindan-Neagoe I. The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge. J Breast Cancer 2018;21:233-43. [PMID: 30275851 DOI: 10.4048/jbc.2018.21.e41] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
215 Byler KG, Setzer WN. Protein Targets of Frankincense: A Reverse Docking Analysis of Terpenoids from Boswellia Oleo-Gum Resins. Medicines (Basel) 2018;5:E96. [PMID: 30200355 DOI: 10.3390/medicines5030096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
216 Yuliana A, Jheng HF, Kawarasaki S, Nomura W, Takahashi H, Ara T, Kawada T, Goto T. β-adrenergic Receptor Stimulation Revealed a Novel Regulatory Pathway via Suppressing Histone Deacetylase 3 to Induce Uncoupling Protein 1 Expression in Mice Beige Adipocyte. Int J Mol Sci 2018;19:E2436. [PMID: 30126161 DOI: 10.3390/ijms19082436] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
217 Bagchi RA, Ferguson BS, Stratton MS, Hu T, Cavasin MA, Sun L, Lin YH, Liu D, Londono P, Song K, Pino MF, Sparks LM, Smith SR, Scherer PE, Collins S, Seto E, McKinsey TA. HDAC11 suppresses the thermogenic program of adipose tissue via BRD2. JCI Insight 2018;3:120159. [PMID: 30089714 DOI: 10.1172/jci.insight.120159] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
218 Cosenza M, Pozzi S. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. Int J Mol Sci 2018;19:E2337. [PMID: 30096875 DOI: 10.3390/ijms19082337] [Cited by in Crossref: 31] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
219 Cermakova K, Hodges HC. Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation. Molecules 2018;23:E1958. [PMID: 30082609 DOI: 10.3390/molecules23081958] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
220 Ahmad S, Alam O, Naim MJ, Shaquiquzzaman M, Alam MM, Iqbal M. Pyrrole: An insight into recent pharmacological advances with structure activity relationship. Eur J Med Chem 2018;157:527-61. [PMID: 30119011 DOI: 10.1016/j.ejmech.2018.08.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 76] [Article Influence: 15.5] [Reference Citation Analysis]
221 Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y, Le Nguyen K, Bishara AT, Mandalia TK, Wang W. Hippo signaling dysfunction induces cancer cell addiction to YAP. Oncogene 2018;37:6414-24. [PMID: 30068939 DOI: 10.1038/s41388-018-0419-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
222 Yoon S, Kook T, Min HK, Kwon DH, Cho YK, Kim M, Shin S, Joung H, Jeong SH, Lee S, Kang G, Park Y, Kim YS, Ahn Y, McMullen JR, Gergs U, Neumann J, Kim KK, Kim J, Nam KI, Kim YK, Kook H, Eom GH. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart. Exp Mol Med 2018;50:1-14. [PMID: 30050113 DOI: 10.1038/s12276-018-0121-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
223 Illiano M, Conte M, Sapio L, Nebbioso A, Spina A, Altucci L, Naviglio S. Forskolin Sensitizes Human Acute Myeloid Leukemia Cells to H3K27me2/3 Demethylases GSKJ4 Inhibitor via Protein Kinase A. Front Pharmacol 2018;9:792. [PMID: 30079022 DOI: 10.3389/fphar.2018.00792] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
224 Bhat SA, Vedpathak DM, Chiplunkar SV. Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function. Front Immunol 2018;9:1615. [PMID: 30072989 DOI: 10.3389/fimmu.2018.01615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
225 Méhul B, Perrin A, Grisendi K, Galindo AN, Dayon L, Ménigot C, Rival Y, Voegel JJ. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line. J Proteomics 2018;187:126-43. [PMID: 30012418 DOI: 10.1016/j.jprot.2018.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
226 Bamodu OA, Kuo KT, Yuan LP, Cheng WH, Lee WH, Ho YS, Chao TY, Yeh CT. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Exp Cell Res 2018;370:519-30. [PMID: 30017934 DOI: 10.1016/j.yexcr.2018.07.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
227 Ganai SA, Farooq Z, Banday S, Altaf M. In silico approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms. Future Med Chem 2018;10:1925-45. [PMID: 29992822 DOI: 10.4155/fmc-2018-0020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
228 Wang B, Lyu H, Pei S, Song D, Ni J, Liu B. Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. Cell Cycle 2018;17:985-96. [PMID: 29969371 DOI: 10.1080/15384101.2018.1464849] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
229 Ming J, Wu S, You T, Wang X, Yu C, Luo P, Zhang A, Pan X. Histone Deacetylation in the Promoter of p16 Is Involved in Fluoride-Induced Human Osteoblast Activation via the Inhibition of Sp1 Binding. Biol Trace Elem Res 2019;188:373-83. [PMID: 29931577 DOI: 10.1007/s12011-018-1413-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
230 Ihn HJ, Lee T, Lee D, Kim JA, Kim K, Lim S, Kim JY, Lee Y, Kim SH, Lee HS, Shin HI, Park EK. A novel benzamide derivative protects ligature-induced alveolar bone erosion by inhibiting NFATc1-mediated osteoclastogenesis. Toxicol Appl Pharmacol 2018;355:9-17. [PMID: 29935282 DOI: 10.1016/j.taap.2018.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
231 Wu X, Wu Y, He L, Wu L, Wang X, Liu Z. Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer. J Cancer 2018;9:2510-7. [PMID: 30026849 DOI: 10.7150/jca.25324] [Cited by in Crossref: 72] [Cited by in F6Publishing: 79] [Article Influence: 18.0] [Reference Citation Analysis]
232 Singh AK, Bishayee A, Pandey AK. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Nutrients. 2018;10:731. [PMID: 29882797 DOI: 10.3390/nu10060731] [Cited by in Crossref: 79] [Cited by in F6Publishing: 99] [Article Influence: 19.8] [Reference Citation Analysis]
233 Abdelfattah MS, Elmallah MIY, Faraag AHI, Hebishy AMS, Ali NH. Heliomycin and tetracinomycin D: anthraquinone derivatives with histone deacetylase inhibitory activity from marine sponge-associated Streptomyces sp. SP9. 3 Biotech 2018;8:282. [PMID: 29881660 DOI: 10.1007/s13205-018-1304-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
234 Hieu DT, Anh DT, Hai P, Huong L, Park EJ, Choi JE, Kang JS, Dung PTP, Han S, Nam N. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Chem Biodiversity 2018;15:e1800027. [DOI: 10.1002/cbdv.201800027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
235 Mackwitz MKW, Hamacher A, Osko JD, Held J, Schöler A, Christianson DW, Kassack MU, Hansen FK. Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]pyridine-Capped Selective HDAC6 Inhibitors. Org Lett 2018;20:3255-8. [PMID: 29790770 DOI: 10.1021/acs.orglett.8b01118] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
236 Hui KF, Yeung PL, Tam KP, Chiang AKS. Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib. Oncotarget 2018;9:25101-14. [PMID: 29861856 DOI: 10.18632/oncotarget.25341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
237 Uba AI, Yelekçi K. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies. Comput Biol Chem 2018;75:131-42. [PMID: 29859380 DOI: 10.1016/j.compbiolchem.2018.05.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
238 Hervouet E. The Promising Role of New Generation HDACis in Anti-Cancer Therapies. EBioMedicine 2018;32:6-7. [PMID: 29754883 DOI: 10.1016/j.ebiom.2018.05.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
239 Sun WW, Jiao S, Sun L, Zhou Z, Jin X, Wang JH. SUN2 Modulates HIV-1 Infection and Latency through Association with Lamin A/C To Maintain the Repressive Chromatin. mBio 2018;9:e02408-17. [PMID: 29717016 DOI: 10.1128/mBio.02408-17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
240 Cheshmedzhieva D, Toshev N, Gerova M, Petrov O, Dudev T. Hydroxamic acid derivatives as histone deacetylase inhibitors: a DFT study of their tautomerism and metal affinities/selectivities. J Mol Model 2018;24:114. [PMID: 29691666 DOI: 10.1007/s00894-018-3651-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
241 Chen D. Dual Targeting Autoimmunity and Cancer: From Biology to Medicine. The Journal of Clinical Pharmacology 2018;58:990-6. [DOI: 10.1002/jcph.1100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
242 Milelli A, Marchetti C, Turrini E, Catanzaro E, Mazzone R, Tomaselli D, Fimognari C, Tumiatti V, Minarini A. Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors. Bioorganic & Medicinal Chemistry Letters 2018;28:1001-4. [DOI: 10.1016/j.bmcl.2018.02.034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
243 Hanigan TW, Danes JM, Taha TY, Frasor J, Petukhov PA. Histone deacetylase inhibitor-based chromatin precipitation for identification of targeted genomic loci. J Biol Methods 2018;5:e88. [PMID: 29682593 DOI: 10.14440/jbm.2018.216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
244 Suraweera A, O'Byrne KJ, Richard DJ. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Front Oncol 2018;8:92. [PMID: 29651407 DOI: 10.3389/fonc.2018.00092] [Cited by in Crossref: 288] [Cited by in F6Publishing: 330] [Article Influence: 72.0] [Reference Citation Analysis]
245 Lin KC, Lin MW, Hsu MN, Yu-Chen G, Chao YC, Tuan HY, Chiang CS, Hu YC. Graphene oxide sensitizes cancer cells to chemotherapeutics by inducing early autophagy events, promoting nuclear trafficking and necrosis. Theranostics 2018;8:2477-87. [PMID: 29721093 DOI: 10.7150/thno.24173] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
246 Xu X, Liu T, Yang J, Chen L, Liu B, Wang L, Jin Q. The First Whole-Cell Proteome- and Lysine-Acetylome-Based Comparison between Trichophyton rubrum Conidial and Mycelial Stages. J Proteome Res 2018;17:1436-51. [PMID: 29564889 DOI: 10.1021/acs.jproteome.7b00793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
247 Russell‐hallinan A, Watson CJ, Baugh JA. Epigenetics of Aberrant Cardiac Wound Healing. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 451-91. [DOI: 10.1002/cphy.c170029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
248 Parrales A, McDonald P, Ottomeyer M, Roy A, Shoenen FJ, Broward M, Bruns T, Thamm DH, Weir SJ, Neville KA, Iwakuma T, Fulbright JM. Comparative oncology approach to drug repurposing in osteosarcoma. PLoS One 2018;13:e0194224. [PMID: 29579058 DOI: 10.1371/journal.pone.0194224] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
249 Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget 2017;8:31478-93. [PMID: 28416758 DOI: 10.18632/oncotarget.15649] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
250 Jose A, Chaitanya MVNL, Kannan E, Madhunapantula SV. Tricaproin Isolated From Simarouba glauca Inhibits the Growth of Human Colorectal Carcinoma Cell Lines by Targeting Class-1 Histone Deacetylases. Front Pharmacol 2018;9:127. [PMID: 29593526 DOI: 10.3389/fphar.2018.00127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
251 Conte M, De Palma R, Altucci L. HDAC inhibitors as epigenetic regulators for cancer immunotherapy. Int J Biochem Cell Biol 2018;98:65-74. [PMID: 29535070 DOI: 10.1016/j.biocel.2018.03.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
252 Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target? Oncotarget 2017;8:28187-202. [PMID: 28390197 DOI: 10.18632/oncotarget.15969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
253 Alam MS, Cooper B, Farris JD, Haldar K. Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice. Sci Rep 2018;8:3875. [PMID: 29497113 DOI: 10.1038/s41598-018-22162-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
254 Farag AB, Ewida HA, Ahmed MS. Design, synthesis, and biological evaluation of novel amide and hydrazide based thioether analogs targeting Histone deacteylase (HDAC) enzymes. European Journal of Medicinal Chemistry 2018;148:73-85. [DOI: 10.1016/j.ejmech.2018.02.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
255 Wu N, Zhu Y, Xu X, Zhu Y, Song Y, Pang L, Chen Z. The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma. J Cancer 2018;9:987-97. [PMID: 29581778 DOI: 10.7150/jca.22861] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
256 Kularatne RN, Washington KE, Bulumulla C, Calubaquib EL, Biewer MC, Oupicky D, Stefan MC. Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy. Biomacromolecules 2018;19:1082-9. [PMID: 29485283 DOI: 10.1021/acs.biomac.8b00221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
257 He JC, Yao W, Wang JM, Schemmer P, Yang Y, Liu Y, Qian YW, Qi WP, Zhang J, Shen Q, Yang T. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors. Oncotarget 2016;7:75441-56. [PMID: 27705912 DOI: 10.18632/oncotarget.12254] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
258 Householder KT, DiPerna DM, Chung EP, Luning AR, Nguyen DT, Stabenfeldt SE, Mehta S, Sirianni RW. pH driven precipitation of quisinostat onto PLA-PEG nanoparticles enables treatment of intracranial glioblastoma. Colloids Surf B Biointerfaces 2018;166:37-44. [PMID: 29533842 DOI: 10.1016/j.colsurfb.2018.02.048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
259 Gregath A, Lu QR. Epigenetic modifications-insight into oligodendrocyte lineage progression, regeneration, and disease. FEBS Lett 2018;592:1063-78. [PMID: 29427507 DOI: 10.1002/1873-3468.12999] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
260 Lu H, Yang XF, Tian XQ, Tang SL, Li LQ, Zhao S, Zheng HC. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells. Oncotarget 2016;7:56508-25. [PMID: 27447743 DOI: 10.18632/oncotarget.10643] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
261 He X, Zhang L, Queme LF, Liu X, Lu A, Waclaw RR, Dong X, Zhou W, Kidd G, Yoon SO, Buonanno A, Rubin JB, Xin M, Nave KA, Trapp BD, Jankowski MP, Lu QR. A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration. Nat Med 2018;24:338-51. [PMID: 29431744 DOI: 10.1038/nm.4483] [Cited by in Crossref: 40] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
262 Zheng S, Guo S, Zhong Q, Zhang C, Liu J, Yang L, Zhang Q, Wang G. Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett 2018;9:149-54. [PMID: 29456804 DOI: 10.1021/acsmedchemlett.7b00504] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
263 Ali I, Conrad RJ, Verdin E, Ott M. Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics. Chem Rev 2018;118:1216-52. [PMID: 29405707 DOI: 10.1021/acs.chemrev.7b00181] [Cited by in Crossref: 107] [Cited by in F6Publishing: 142] [Article Influence: 26.8] [Reference Citation Analysis]
264 Khan S, Iqbal M, Tariq M, Baig SM, Abbas W. Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins. Clin Epigenetics 2018;10:14. [PMID: 29441145 DOI: 10.1186/s13148-018-0441-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
265 Souza BK, da Costa Lopez PL, Menegotto PR, Vieira IA, Kersting N, Abujamra AL, Brunetto AT, Brunetto AL, Gregianin L, de Farias CB, Thiele CJ, Roesler R. Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. Mol Neurobiol 2018;55:7242-58. [PMID: 29397557 DOI: 10.1007/s12035-018-0874-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
266 Tago T, Toyohara J. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases. Molecules 2018;23:E300. [PMID: 29385079 DOI: 10.3390/molecules23020300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
267 Lorenzo Pisarello M, Masyuk TV, Gradilone SA, Masyuk AI, Ding JF, Lee PY, LaRusso NF. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. Am J Pathol 2018;188:981-94. [PMID: 29366679 DOI: 10.1016/j.ajpath.2017.12.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
268 Saenglee S, Senawong G, Jogloy S, Sripa B, Senawong T. Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells. Biomed Pharmacother 2018;98:233-41. [PMID: 29268244 DOI: 10.1016/j.biopha.2017.12.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
269 Tarasenko N, Chekroun-Setti H, Nudelman A, Rephaeli A. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. J Cell Biochem 2018;119:3417-28. [PMID: 29135083 DOI: 10.1002/jcb.26512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
270 Uba Aİ, Yelekçi K. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors. Turk J Biol 2017;41:901-18. [PMID: 30814855 DOI: 10.3906/biy-1701-26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
271 Lee JW, Yang DH, Park S, Han HK, Park JW, Kim BY, Um SH, Moon EY. Trichostatin A resistance is facilitated by HIF-1α acetylation in HeLa human cervical cancer cells under normoxic conditions. Oncotarget 2018;9:2035-49. [PMID: 29416751 DOI: 10.18632/oncotarget.23327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
272 Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain 2017;140:3081-104. [PMID: 29053785 DOI: 10.1093/brain/awx198] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 14.0] [Reference Citation Analysis]
273 Moretti NS, Cestari I, Anupama A, Stuart K, Schenkman S. Comparative Proteomic Analysis of Lysine Acetylation in Trypanosomes. J Proteome Res 2018;17:374-85. [PMID: 29168382 DOI: 10.1021/acs.jproteome.7b00603] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
274 Davies G, Lobanova L, Dawicki W, Groot G, Gordon JR, Bowen M, Harkness T, Arnason T. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLoS One 2017;12:e0187191. [PMID: 29211738 DOI: 10.1371/journal.pone.0187191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
275 Anantharaju PG, Reddy DB, Padukudru MA, Chitturi CMK, Vimalambike MG, Madhunapantula SV. Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC). PLoS One 2017;12:e0186208. [PMID: 29190639 DOI: 10.1371/journal.pone.0186208] [Cited by in Crossref: 22] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
276 Librizzi M, Caradonna F, Cruciata I, Dębski J, Sansook S, Dadlez M, Spencer J, Luparello C. Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA. Chem Res Toxicol 2017;30:2187-96. [PMID: 29129070 DOI: 10.1021/acs.chemrestox.7b00269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
277 Ganai SA, Abdullah E, Rashid R, Altaf M. Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders. Front Mol Neurosci 2017;10:357. [PMID: 29170627 DOI: 10.3389/fnmol.2017.00357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
278 Yang W, Sun Z, Hua C, Wang Q, Xu W, Deng Q, Pan Y, Lu L, Jiang S. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. Microbes Infect 2018;20:626-34. [PMID: 29126877 DOI: 10.1016/j.micinf.2017.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
279 Castañeda CA, Wolfson NA, Leng KR, Kuo YM, Andrews AJ, Fierke CA. HDAC8 substrate selectivity is determined by long- and short-range interactions leading to enhanced reactivity for full-length histone substrates compared with peptides. J Biol Chem 2017;292:21568-77. [PMID: 29109148 DOI: 10.1074/jbc.M117.811026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
280 Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev 2017;121:124-32. [PMID: 29079534 DOI: 10.1016/j.addr.2017.10.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
281 Chrun ES, Modolo F, Daniel FI. Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis. Pathology - Research and Practice 2017;213:1329-39. [DOI: 10.1016/j.prp.2017.06.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
282 Thompson LL, Jeusset LM, Lepage CC, McManus KJ. Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer. Cancers (Basel) 2017;9:E151. [PMID: 29104272 DOI: 10.3390/cancers9110151] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
283 Harding RJ, Ferreira de Freitas R, Collins P, Franzoni I, Ravichandran M, Ouyang H, Juarez-ornelas KA, Lautens M, Schapira M, von Delft F, Santhakumar V, Arrowsmith CH. Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin. J Med Chem 2017;60:9090-6. [DOI: 10.1021/acs.jmedchem.7b00933] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
284 Dolskiy AA, Pustylnyak VO, Yarushkin AA, Lemskaya NA, Yudkin DV. Inhibitors of Histone Deacetylases Are Weak Activators of the FMR1 Gene in Fragile X Syndrome Cell Lines. Biomed Res Int 2017;2017:3582601. [PMID: 29209628 DOI: 10.1155/2017/3582601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
285 Ursu O, Gosline SJC, Beeharry N, Fink L, Bhattacharjee V, Huang SC, Zhou Y, Yen T, Fraenkel E. Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLoS One 2017;12:e0185650. [PMID: 29023490 DOI: 10.1371/journal.pone.0185650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
286 Patil M, Choudhari AS, Pandita S, Islam MA, Raina P, Kaul-Ghanekar R. Cinnamaldehyde, Cinnamic Acid, and Cinnamyl Alcohol, the Bioactives of Cinnamomum cassia Exhibit HDAC8 Inhibitory Activity: An In vitro and In silico Study. Pharmacogn Mag 2017;13:S645-51. [PMID: 29142427 DOI: 10.4103/pm.pm_389_16] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
287 Al-keilani MS, Al-sawalha NA. Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms. Chem Res Toxicol 2017;30:1767-77. [DOI: 10.1021/acs.chemrestox.7b00149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
288 Strebl MG, Campbell AJ, Zhao WN, Schroeder FA, Riley MM, Chindavong PS, Morin TM, Haggarty SJ, Wagner FF, Ritter T, Hooker JM. HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination. ACS Cent Sci 2017;3:1006-14. [PMID: 28979942 DOI: 10.1021/acscentsci.7b00274] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
289 Eriksson M, Hååg P, Brzozowska B, Lipka M, Lisowska H, Lewensohn R, Wojcik A, Viktorsson K, Lundholm L. Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment. Int J Radiat Oncol Biol Phys 2018;100:174-87. [PMID: 29107335 DOI: 10.1016/j.ijrobp.2017.09.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
290 Hanigan TW, Aboukhatwa SM, Taha TY, Frasor J, Petukhov PA. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity. Cell Chem Biol 2017;24:1356-1367.e8. [PMID: 28943357 DOI: 10.1016/j.chembiol.2017.08.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
291 Ambrosi M, Orsini A, Verrotti A, Striano P. Medical management for neurosurgical related seizures. Expert Opinion on Pharmacotherapy 2017;18:1491-8. [DOI: 10.1080/14656566.2017.1373092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
292 Pasyukova EG, Vaiserman AM. HDAC inhibitors: A new promising drug class in anti-aging research. Mechanisms of Ageing and Development 2017;166:6-15. [DOI: 10.1016/j.mad.2017.08.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
293 Scholte LL, Mourão MM, Pais FS, Melesina J, Robaa D, Volpini AC, Sippl W, Pierce RJ, Oliveira G, Nahum LA. Evolutionary relationships among protein lysine deacetylases of parasites causing neglected diseases. Infection, Genetics and Evolution 2017;53:175-88. [DOI: 10.1016/j.meegid.2017.05.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
294 Yu Z, Taniguchi J, Wei Y, Pandian GN, Hashiya K, Bando T, Sugiyama H. Antiproliferative and apoptotic activities of sequence-specific histone acetyltransferase inhibitors. European Journal of Medicinal Chemistry 2017;138:320-7. [DOI: 10.1016/j.ejmech.2017.06.037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
295 Chen Y, de Bruyn Kops C, Kirchmair J. Data Resources for the Computer-Guided Discovery of Bioactive Natural Products. J Chem Inf Model 2017;57:2099-111. [DOI: 10.1021/acs.jcim.7b00341] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 17.0] [Reference Citation Analysis]
296 Simões-Pires CA, Zwick V, Cretton S, Cuendet M. Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS. J Vis Exp 2017. [PMID: 28829415 DOI: 10.3791/55878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
297 Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances. Blood Rev 2018;32:8-28. [PMID: 28802908 DOI: 10.1016/j.blre.2017.08.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
298 Natanzon Y, Goode EL, Cunningham JM. Epigenetics in ovarian cancer. Semin Cancer Biol 2018;51:160-9. [PMID: 28782606 DOI: 10.1016/j.semcancer.2017.08.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 53] [Article Influence: 8.0] [Reference Citation Analysis]
299 Kamarulzaman NS, Dewadas HD, Leow CY, Yaacob NS, Mokhtar NF. The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer. Cancer Cell Int 2017;17:74. [PMID: 28785170 DOI: 10.1186/s12935-017-0442-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
300 Janaki Ramaiah M, Naushad SM, Lavanya A, Srinivas C, Anjana Devi T, Sampathkumar S, Dharan DB, Bhadra MP. Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects. Gene 2017;627:379-86. [PMID: 28668345 DOI: 10.1016/j.gene.2017.06.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
301 Stratton MS, Haldar SM, McKinsey TA. BRD4 inhibition for the treatment of pathological organ fibrosis. F1000Res 2017;6:F1000 Faculty Rev-1015. [PMID: 28721198 DOI: 10.12688/f1000research.11339.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
302 Krieger V, Hamacher A, Gertzen CGW, Senger J, Zwinderman MRH, Marek M, Romier C, Dekker FJ, Kurz T, Jung M, Gohlke H, Kassack MU, Hansen FK. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups. J Med Chem 2017;60:5493-506. [PMID: 28574690 DOI: 10.1021/acs.jmedchem.7b00197] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
303 van den Bosch T, Kwiatkowski M, Bischoff R, Dekker FJ. Targeting transcription factor lysine acetylation in inflammatory airway diseases. Epigenomics 2017;9:1013-28. [PMID: 28617138 DOI: 10.2217/epi-2017-0027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
304 Tchio Mantho CI, Harbuzariu A, Gonzalez-Perez RR. Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer. World J Clin Oncol 2017; 8(3): 178-189 [PMID: 28638788 DOI: 10.5306/wjco.v8.i3.178] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
305 Mari-Alexandre J, Diaz-Lagares A, Villalba M, Juan O, Crujeiras AB, Calvo A, Sandoval J. Translating cancer epigenomics into the clinic: focus on lung cancer. Transl Res 2017;189:76-92. [PMID: 28644958 DOI: 10.1016/j.trsl.2017.05.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
306 Allen SC, Mamotte CDS. Pleiotropic and Adverse Effects of Statins-Do Epigenetics Play a Role? J Pharmacol Exp Ther 2017;362:319-26. [PMID: 28576976 DOI: 10.1124/jpet.117.242081] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
307 Yoshida M, Kudo N, Kosono S, Ito A. Chemical and structural biology of protein lysine deacetylases. Proc Jpn Acad Ser B Phys Biol Sci 2017;93:297-321. [PMID: 28496053 DOI: 10.2183/pjab.93.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
308 Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics 2017;9:59. [PMID: 28572863 DOI: 10.1186/s13148-017-0358-y] [Cited by in Crossref: 82] [Cited by in F6Publishing: 90] [Article Influence: 16.4] [Reference Citation Analysis]
309 Niederberger E, Resch E, Parnham MJ, Geisslinger G. Drugging the pain epigenome. Nat Rev Neurol 2017;13:434-47. [PMID: 28548108 DOI: 10.1038/nrneurol.2017.68] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
310 Hegedüs L, Padányi R, Molnár J, Pászty K, Varga K, Kenessey I, Sárközy E, Wolf M, Grusch M, Hegyi Z, Homolya L, Aigner C, Garay T, Hegedüs B, Tímár J, Kállay E, Enyedi Á. Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK. Front Oncol 2017;7:95. [PMID: 28596940 DOI: 10.3389/fonc.2017.00095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
311 Lin TW, Chen MT, Lin LT, Huang PI, Lo WL, Yang YP, Lu KH, Chen YW, Chiou SH, Wu CW. TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma. Oncotarget 2017;8:56612-25. [PMID: 28915616 DOI: 10.18632/oncotarget.17979] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
312 Anantharaju PG, Reddy BD, Padukudru MA, Kumari Chitturi CM, Vimalambike MG, Madhunapantula SV. Naturally occurring benzoic acid derivatives retard cancer cell growth by inhibiting histone deacetylases (HDAC). Cancer Biol Ther 2017;18:492-504. [PMID: 28506198 DOI: 10.1080/15384047.2017.1324374] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
313 Mathur S, Hoskins C. Drug development: Lessons from nature. Biomed Rep 2017;6:612-4. [PMID: 28584631 DOI: 10.3892/br.2017.909] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 12.0] [Reference Citation Analysis]
314 Wang Y, Wallach J, Duane S, Wang Y, Wu J, Wang J, Adejare A, Ma H. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs. Drug Des Devel Ther 2017;11:1369-82. [PMID: 28496307 DOI: 10.2147/DDDT.S124977] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
315 Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res 2017;23:4780-92. [PMID: 28465444 DOI: 10.1158/1078-0432.CCR-16-2622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
316 Traoré MDM, Zwick V, Simões-Pires CA, Nurisso A, Issa M, Cuendet M, Maynadier M, Wein S, Vial H, Jamet H, Wong YS. Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6. ACS Omega 2017;2:1550-62. [PMID: 30023639 DOI: 10.1021/acsomega.6b00481] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
317 Kobayashi Y, Gélinas C, Dougherty JP. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells. J Gen Virol 2017;98:799-809. [PMID: 28113052 DOI: 10.1099/jgv.0.000716] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
318 Batlevi CL, Crump M, Andreadis C, Rizzieri D, Assouline SE, Fox S, van der Jagt RHC, Copeland A, Potvin D, Chao R, Younes A. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol 2017;178:434-41. [PMID: 28440559 DOI: 10.1111/bjh.14698] [Cited by in Crossref: 44] [Cited by in F6Publishing: 53] [Article Influence: 8.8] [Reference Citation Analysis]
319 Leus NG, van den Bosch T, van der Wouden PE, Krist K, Ourailidou ME, Eleftheriadis N, Kistemaker LE, Bos S, Gjaltema RA, Mekonnen SA, Bischoff R, Gosens R, Haisma HJ, Dekker FJ. HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice. Sci Rep 2017;7:45047. [PMID: 28344354 DOI: 10.1038/srep45047] [Cited by in Crossref: 40] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
320 Wahid B, Ali A, Rafique S, Idrees M. New Insights into the Epigenetics of Hepatocellular Carcinoma. Biomed Res Int 2017;2017:1609575. [PMID: 28401148 DOI: 10.1155/2017/1609575] [Cited by in Crossref: 37] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
321 Tarasenko N, Nudelman A, Rozic G, Cutts SM, Rephaeli A. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. Invest New Drugs 2017;35:412-26. [DOI: 10.1007/s10637-017-0448-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
322 van den Bosch T, Leus NGJ, Wapenaar H, Boichenko A, Hermans J, Bischoff R, Haisma HJ, Dekker FJ. A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices. Pulm Pharmacol Ther 2017;44:88-95. [PMID: 28323055 DOI: 10.1016/j.pupt.2017.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
323 Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov 2017;16:241-63. [PMID: 28280262 DOI: 10.1038/nrd.2016.256] [Cited by in Crossref: 159] [Cited by in F6Publishing: 151] [Article Influence: 31.8] [Reference Citation Analysis]
324 Chrun ES, Modolo F, Vieira D, Borges-Júnior Á, Castro RG, Daniel FI. Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma. Oral Dis 2017;23:505-10. [PMID: 28107582 DOI: 10.1111/odi.12641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
325 Ahmed M, Chaudhari K, Babaei-jadidi R, Dekker LV, Shams Nateri A. Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells: Drugs Targeting Cancer Stem Cells. Stem Cells 2017;35:839-50. [DOI: 10.1002/stem.2579] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
326 Pham-the H, Casañola-martin G, Diéguez-santana K, Nguyen-hai N, Ngoc N, Vu-duc L, Le-thi-thu H. Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries. SAR and QSAR in Environmental Research 2017;28:199-220. [DOI: 10.1080/1062936x.2017.1294198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
327 Prachayasittikul V, Prathipati P, Pratiwi R, Phanus-Umporn C, Malik AA, Schaduangrat N, Seenprachawong K, Wongchitrat P, Supokawej A, Prachayasittikul V, Wikberg JE, Nantasenamat C. Exploring the epigenetic drug discovery landscape. Expert Opin Drug Discov 2017;12:345-62. [PMID: 28276705 DOI: 10.1080/17460441.2017.1295954] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
328 Bayat Mokhtari R, Baluch N, Ka Hon Tsui M, Kumar S, S Homayouni T, Aitken K, Das B, Baruchel S, Yeger H. Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma. BMC Cancer 2017;17:156. [PMID: 28235409 DOI: 10.1186/s12885-017-3126-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
329 de Oliveira FL, Carneiro K, Brito JM, Cabanel M, Pereira JX, Paiva LA, Syn W, Henderson NC, El-Cheikh MC. Galectin-3, histone deacetylases, and Hedgehog signaling: Possible convergent targets in schistosomiasis-induced liver fibrosis. PLoS Negl Trop Dis 2017;11:e0005137. [PMID: 28231240 DOI: 10.1371/journal.pntd.0005137] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
330 Zagni C, Floresta G, Monciino G, Rescifina A. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. Med Res Rev 2017;37:1373-428. [PMID: 28181261 DOI: 10.1002/med.21437] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 12.2] [Reference Citation Analysis]
331 Biswas S, Rao CM. Epigenetics in cancer: Fundamentals and Beyond. Pharmacol Ther 2017;173:118-34. [PMID: 28188812 DOI: 10.1016/j.pharmthera.2017.02.011] [Cited by in Crossref: 105] [Cited by in F6Publishing: 113] [Article Influence: 21.0] [Reference Citation Analysis]
332 Schuetze KB, Stratton MS, Blakeslee WW, Wempe MF, Wagner FF, Holson EB, Kuo YM, Andrews AJ, Gilbert TM, Hooker JM, McKinsey TA. Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts. J Pharmacol Exp Ther 2017;361:140-50. [PMID: 28174211 DOI: 10.1124/jpet.116.237701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
333 Mccuaig R, Wu F, Dunn J, Rao S, Dahlstrom JE. The biological and clinical significance of stromal-epithelial interactions in breast cancer. Pathology 2017;49:133-40. [DOI: 10.1016/j.pathol.2016.10.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
334 Simões-Pires CA, Bertrand P, Cuendet M. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137). Expert Opin Ther Pat 2017;27:229-36. [PMID: 28092474 DOI: 10.1080/13543776.2017.1282945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
335 Polychronidou G, Karavasilis V, Pollack SM, Huang PH, Lee A, Jones RL. Novel therapeutic approaches in chondrosarcoma. Future Oncol 2017;13:637-48. [PMID: 28133974 DOI: 10.2217/fon-2016-0226] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 12.2] [Reference Citation Analysis]
336 Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJS, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica 2017;102:903-9. [PMID: 28126962 DOI: 10.3324/haematol.2016.154377] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
337 Cacan E. Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells: Regulation of immune genes in ovarian cancer. Cell Biol Int 2017;41:328-39. [DOI: 10.1002/cbin.10729] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
338 Cacan E. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. Journal of Chemotherapy 2017;29:173-8. [DOI: 10.1080/1120009x.2016.1277007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
339 Frère A, Baroni A, Hendrick E, Delvigne A, Orange F, Peulen O, Dakwar GR, Diricq J, Dubois P, Evrard B, Remaut K, Braeckmans K, De Smedt SC, Laloy J, Dogné J, Feller G, Mespouille L, Mottet D, Piel G. PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy. ACS Appl Mater Interfaces 2017;9:2181-95. [DOI: 10.1021/acsami.6b15064] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
340 Zhang Y, Li F, Kang J. Screening of histone deacetylase 1 inhibitors in natural products by capillary electrophoresis. Anal Methods 2017;9:5502-8. [DOI: 10.1039/c7ay01428g] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
341 Ganai SA. Plant-derived flavone Apigenin: The small-molecule with promising activity against therapeutically resistant prostate cancer. Biomedicine & Pharmacotherapy 2017;85:47-56. [DOI: 10.1016/j.biopha.2016.11.130] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
342 Ravera M, Gabano E, Zanellato I, Gallina A, Perin E, Arrais A, Cantamessa S, Osella D. Cisplatin and valproate released from the bifunctional [Pt (IV) Cl 2 (NH 3 ) 2 (valproato) 2 ] antitumor prodrug or from liposome formulations: who does what? Dalton Trans 2017;46:1559-66. [DOI: 10.1039/c6dt03749f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
343 Grabarska A, Łuszczki JJ, Nowosadzka E, Gumbarewicz E, Jeleniewicz W, Dmoszyńska-Graniczka M, Kowalczuk K, Kupisz K, Polberg K, Stepulak A. Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. J Cancer 2017;8:19-28. [PMID: 28123594 DOI: 10.7150/jca.16655] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
344 Kgatle MM, Setshedi M, Hairwadzi HN. Hepatoepigenetic Alterations in Viral and Nonviral-Induced Hepatocellular Carcinoma. Biomed Res Int. 2016;2016:3956485. [PMID: 28105421 DOI: 10.1155/2016/3956485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
345 Deutsch E, Moyal EC, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S. A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors. Oncotarget 2017;8:56199-209. [PMID: 28915584 DOI: 10.18632/oncotarget.14147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
346 Silverman BR, Shi J. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications. Int J Mol Sci 2016;17:E2138. [PMID: 27999365 DOI: 10.3390/ijms17122138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
347 Stoney PN, Rodrigues D, Helfer G, Khatib T, Ashton A, Hay EA, Starr R, Kociszewska D, Morgan P, McCaffery P. A seasonal switch in histone deacetylase gene expression in the hypothalamus and their capacity to modulate nuclear signaling pathways. Brain Behav Immun 2017;61:340-52. [PMID: 27993690 DOI: 10.1016/j.bbi.2016.12.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
348 Hoffend NC, Magner WJ, Tomasi TB. The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat. Epigenetics 2017;12:105-12. [PMID: 27935420 DOI: 10.1080/15592294.2016.1267886] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
349 Zwick V, Allard PM, Ory L, Simões-Pires CA, Marcourt L, Gindro K, Wolfender JL, Cuendet M. UHPLC-MS-based HDAC Assay Applied to Bio-guided Microfractionation of Fungal Extracts. Phytochem Anal 2017;28:93-100. [PMID: 27921344 DOI: 10.1002/pca.2652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
350 Majchrzak-Celińska A, Baer-Dubowska W. Pharmacoepigenetics: an element of personalized therapy? Expert Opin Drug Metab Toxicol 2017;13:387-98. [PMID: 27860490 DOI: 10.1080/17425255.2017.1260546] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
351 Losson H, Schnekenburger M, Dicato M, Diederich M. Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer. Molecules 2016;21:E1608. [PMID: 27886118 DOI: 10.3390/molecules21111608] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
352 Kiran Rompicharla SV, Trivedi P, Kumari P, Ghanta P, Ghosh B, Biswas S. Polymeric micelles of suberoylanilide hydroxamic acid to enhance the anticancer potential in vitro and in vivo. Nanomedicine (Lond) 2017;12:43-58. [PMID: 27879153 DOI: 10.2217/nnm-2016-0321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
353 Pan CH, Chang YF, Lee MS, Wen BC, Ko JC, Liang SK, Liang MC. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer 2016;16:857. [PMID: 27821078 DOI: 10.1186/s12885-016-2888-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
354 Vaiserman AM, Lushchak OV, Koliada AK. Anti-aging pharmacology: Promises and pitfalls. Ageing Res Rev 2016;31:9-35. [PMID: 27524412 DOI: 10.1016/j.arr.2016.08.004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 15.0] [Reference Citation Analysis]
355 Lee S, Jang J, Jeon H, Lee J, Yoo SM, Park J, Lee MS. Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species. J Microbiol 2016;54:782-8. [PMID: 27796928 DOI: 10.1007/s12275-016-6388-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
356 Huang T, Lin C, Zhong LL, Zhao L, Zhang G, Lu A, Wu J, Bian Z. Targeting histone methylation for colorectal cancer. Therap Adv Gastroenterol 2017;10:114-31. [PMID: 28286564 DOI: 10.1177/1756283X16671287] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
357 Melkova Z, Shankaran P, Madlenakova M, Bodor J. Current views on HIV-1 latency, persistence, and cure. Folia Microbiol (Praha) 2017;62:73-87. [PMID: 27709447 DOI: 10.1007/s12223-016-0474-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
358 Arlt A, Schäfer H. Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma. Expert Opin Investig Drugs 2016;25:1251-4. [PMID: 27666721 DOI: 10.1080/13543784.2016.1240167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
359 Choi KY, Kim YK. Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry 2016;70:134-47. [PMID: 27072378 DOI: 10.1016/j.pnpbp.2016.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
360 Narita K, Matsuhara K, Itoh J, Akiyama Y, Dan S, Yamori T, Ito A, Yoshida M, Katoh T. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors. European Journal of Medicinal Chemistry 2016;121:592-609. [DOI: 10.1016/j.ejmech.2016.05.031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
361 Ganai SA, Banday S, Farooq Z, Altaf M. Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders. Pharmacology & Therapeutics 2016;166:106-22. [DOI: 10.1016/j.pharmthera.2016.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
362 Suresh PS, Devaraj VC, Srinivas NR, Mullangi R. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomed Chromatogr 2017;31. [PMID: 27511598 DOI: 10.1002/bmc.3807] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
363 Garnaud C, Champleboux M, Maubon D, Cornet M, Govin J. Histone Deacetylases and Their Inhibition in Candida Species. Front Microbiol 2016;7:1238. [PMID: 27547205 DOI: 10.3389/fmicb.2016.01238] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
364 Braun CJ, Hemann MT. Rewiring the solid tumor epigenome for cancer therapy. Expert Review of Anticancer Therapy 2016;16:977-87. [DOI: 10.1080/14737140.2016.1212663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
365 Manal M, Chandrasekar M, Gomathi Priya J, Nanjan M. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorganic Chemistry 2016;67:18-42. [DOI: 10.1016/j.bioorg.2016.05.005] [Cited by in Crossref: 124] [Cited by in F6Publishing: 126] [Article Influence: 20.7] [Reference Citation Analysis]
366 Zou Z, Luo X, Nie P, Wu B, Zhang T, Wei Y, Wang W, Geng G, Jiang J, Mi Y. Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun 2016;478:227-33. [PMID: 27425252 DOI: 10.1016/j.bbrc.2016.07.063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
367 McGurk L, Berson A, Bonini NM. Drosophila as an In Vivo Model for Human Neurodegenerative Disease. Genetics 2015;201:377-402. [PMID: 26447127 DOI: 10.1534/genetics.115.179457] [Cited by in Crossref: 159] [Cited by in F6Publishing: 143] [Article Influence: 26.5] [Reference Citation Analysis]
368 El-Mowafy AM, Katary MM, Pye C, Ibrahim AS, Elmarakby AA. Novel molecular triggers underlie valproate-induced liver injury and its alleviation by the omega-3 fatty acid DHA: role of inflammation and apoptosis. Heliyon 2016;2:e00130. [PMID: 27441301 DOI: 10.1016/j.heliyon.2016.e00130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
369 Lomberk GA, Iovanna J, Urrutia R. The promise of epigenomic therapeutics in pancreatic cancer. Epigenomics 2016;8:831-42. [PMID: 27337224 DOI: 10.2217/epi-2015-0016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
370 Abdalla MA. Medicinal significance of naturally occurring cyclotetrapeptides. J Nat Med 2016;70:708-20. [PMID: 27300506 DOI: 10.1007/s11418-016-1001-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
371 Sotolongo A, Zakia Mónica F, Kots A, Xiao H, Liu J, Seto E, Bian K, Murad F. Epigenetic regulation of soluble guanylate cyclase (sGC) β1 in breast cancer cells. FASEB j 2016;30:3171-80. [DOI: 10.1096/fj.201600339r] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
372 Khan FS, Ali I, Afridi UK, Ishtiaq M, Mehmood R. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatol Int 2017;11:45-53. [PMID: 27271356 DOI: 10.1007/s12072-016-9743-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
373 Srinivas NR. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica 2017;47:354-68. [PMID: 27226420 DOI: 10.1080/00498254.2016.1184356] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
374 Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem 2016;121:451-83. [PMID: 27318122 DOI: 10.1016/j.ejmech.2016.05.047] [Cited by in Crossref: 160] [Cited by in F6Publishing: 174] [Article Influence: 26.7] [Reference Citation Analysis]
375 Ganai SA. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies. J Chemother 2016;28:247-54. [PMID: 27121910 DOI: 10.1080/1120009X.2016.1145375] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
376 Ganai SA. Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer. Biomed Pharmacother 2016;81:250-7. [PMID: 27261601 DOI: 10.1016/j.biopha.2016.04.022] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
377 Toki S, Goleniewska K, Reiss S, Zhou W, Newcomb DC, Bloodworth MH, Stier MT, Boyd KL, Polosukhin VV, Subramaniam S, Peebles RS Jr. The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation. Thorax 2016;71:633-45. [PMID: 27071418 DOI: 10.1136/thoraxjnl-2015-207728] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
378 Cincinelli R, Zwick V, Musso L, Zuco V, De Cesare M, Zunino F, Simoes-pires C, Nurisso A, Giannini G, Cuendet M, Dallavalle S. Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity. European Journal of Medicinal Chemistry 2016;112:99-105. [DOI: 10.1016/j.ejmech.2016.02.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
379 Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, Morschhauser F, Karlin L, Broussais F, Rezai K, Herait P, Kahatt C, Lokiec F, Salles G, Facon T, Palumbo A, Cunningham D, Zucca E, Thieblemont C. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. The Lancet Haematology 2016;3:e196-204. [DOI: 10.1016/s2352-3026(16)00021-1] [Cited by in Crossref: 224] [Cited by in F6Publishing: 257] [Article Influence: 37.3] [Reference Citation Analysis]
380 Berthon C, Raffoux E, Thomas X, Vey N, Gomez-roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. The Lancet Haematology 2016;3:e186-95. [DOI: 10.1016/s2352-3026(15)00247-1] [Cited by in Crossref: 234] [Cited by in F6Publishing: 264] [Article Influence: 39.0] [Reference Citation Analysis]
381 López JE, Sullivan ED, Fierke CA. Metal-dependent Deacetylases: Cancer and Epigenetic Regulators. ACS Chem Biol 2016;11:706-16. [PMID: 26907466 DOI: 10.1021/acschembio.5b01067] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
382 Garcia-Rodriguez L, Jones L, Chen KM, Datta I, Divine G, Worsham MJ. Causal network analysis of head and neck keloid tissue identifies potential master regulators. Laryngoscope 2016;126:E319-24. [PMID: 26990118 DOI: 10.1002/lary.25958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
383 Sasaki K, Yoshida M. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors. Drug Discovery Today: Technologies 2016;19:51-6. [DOI: 10.1016/j.ddtec.2016.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
384 Tedjaseputra A, Galli S, Ibrahim M, Harrison C, Mclornan D. Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects. Expert Opinion on Orphan Drugs 2016;4:417-27. [DOI: 10.1517/21678707.2016.1149467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
385 Ganesan A. Multitarget Drugs: an Epigenetic Epiphany. ChemMedChem 2016;11:1227-41. [PMID: 26891251 DOI: 10.1002/cmdc.201500394] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 9.3] [Reference Citation Analysis]
386 Alam MS, Getz M, Haldar K. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model. Sci Transl Med 2016;8:326ra23-326ra23. [DOI: 10.1126/scitranslmed.aad9407] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
387 Wang J, Wen L, Wang Y, Chen F. Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo. DNA Cell Biol 2016;35:203-8. [PMID: 26859163 DOI: 10.1089/dna.2015.3037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
388 Hsu CW, Shou D, Huang R, Khuc T, Dai S, Zheng W, Klumpp-Thomas C, Xia M. Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay. J Biomol Screen 2016;21:643-52. [PMID: 26858181 DOI: 10.1177/1087057116629381] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
389 Ganai SA. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Pharmaceutical Biology 2016;54:1926-35. [DOI: 10.3109/13880209.2015.1135966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
390 Baig S, Seevasant I, Mohamad J, Mukheem A, Huri HZ, Kamarul T. Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis. 2016;7:e2058. [PMID: 26775709 DOI: 10.1038/cddis.2015.275] [Cited by in Crossref: 153] [Cited by in F6Publishing: 166] [Article Influence: 25.5] [Reference Citation Analysis]
391 Su J, Wang F, Cai Y, Jin J. The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis. Int J Mol Sci 2016;17:E99. [PMID: 26784169 DOI: 10.3390/ijms17010099] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
392 Wen J, Bao Y, Niu Q, Yang J, Fan Y, Li J, Jing Y, Zhao L, Liu D. Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy. Eur J Med Chem 2016;109:350-9. [PMID: 26814680 DOI: 10.1016/j.ejmech.2016.01.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
393 Simon RP, Robaa D, Alhalabi Z, Sippl W, Jung M. KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases. J Med Chem. 2016;59:1249-1270. [PMID: 26701186 DOI: 10.1021/acs.jmedchem.5b01502] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
394 Dvorakova M, Vanek T. Histone deacetylase inhibitors for the treatment of cancer stem cells. Med Chem Commun 2016;7:2217-31. [DOI: 10.1039/c6md00297h] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
395 Takada M, Fujimoto M, Motomura H, Hosomi K. Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases. Int J Med Sci 2016;13:48-59. [PMID: 26816494 DOI: 10.7150/ijms.13834] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
396 Ourailidou ME, Leus NGJ, Krist K, Lenoci A, Mai A, Dekker FJ. Chemical epigenetics to assess the role of HDAC1–3 inhibition in macrophage pro-inflammatory gene expression. Med Chem Commun 2016;7:2184-90. [DOI: 10.1039/c6md00375c] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
397 Wen J, Niu Q, Liu J, Bao Y, Yang J, Luan S, Fan Y, Liu D, Zhao L. Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1 H -pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study. Bioorganic & Medicinal Chemistry Letters 2016;26:375-9. [DOI: 10.1016/j.bmcl.2015.12.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
398 Zwick V, Nurisso A, Simões-pires C, Bouchet S, Martinet N, Lehotzky A, Ovadi J, Cuendet M, Blanquart C, Bertrand P. Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. Bioorganic & Medicinal Chemistry Letters 2016;26:154-9. [DOI: 10.1016/j.bmcl.2015.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
399 Wang TY, Jia YL, Zhang X, Sun QL, Li YC, Zhang JH, Zhao CP, Wang XY, Wang L. Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome. Sci Rep 2015;5:18443. [PMID: 26675280 DOI: 10.1038/srep18443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
400 Atrian F, Lelièvre SA. Mining the epigenetic landscape of tissue polarity in search of new targets for cancer therapy. Epigenomics 2015;7:1313-25. [PMID: 26646365 DOI: 10.2217/epi.15.83] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
401 Shinjo K, Kondo Y. Targeting cancer epigenetics: Linking basic biology to clinical medicine. Adv Drug Deliv Rev 2015;95:56-64. [PMID: 26494398 DOI: 10.1016/j.addr.2015.10.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
402 Zhang Y, Zhang B. Trichostatin A, an Inhibitor of Histone Deacetylase, Inhibits the Viability and Invasiveness of Hypoxic Rheumatoid Arthritis Fibroblast-Like Synoviocytes via PI3K/Akt Signaling. J Biochem Mol Toxicol 2016;30:163-9. [PMID: 26509796 DOI: 10.1002/jbt.21774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
403 Ganai SA. Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Arch Pharm Res . [DOI: 10.1007/s12272-015-0673-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
404 Sherwani SI, Khan HA. Role of 5-hydroxymethylcytosine in neurodegeneration. Gene 2015;570:17-24. [DOI: 10.1016/j.gene.2015.06.052] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
405 Musso L, Cincinelli R, Zuco V, Zunino F, Nurisso A, Cuendet M, Giannini G, Vesci L, Pisano C, Dallavalle S. Investigation on the ZBG-functionality of phenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 2015;25:4457-60. [DOI: 10.1016/j.bmcl.2015.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
406 Yoshida M, Sasahara K, Doi T. Total synthesis of cyclodepsipeptide spiruchostatin A on silyl-linked polymer-support. Tetrahedron 2015;71:7647-53. [DOI: 10.1016/j.tet.2015.07.064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
407 Szymanski W, Ourailidou ME, Velema WA, Dekker FJ, Feringa BL. Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy. Chemistry 2015;21:16517-24. [PMID: 26418117 DOI: 10.1002/chem.201502809] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 11.6] [Reference Citation Analysis]
408 Ramachandran S, Ient J, Göttgens EL, Krieg AJ, Hammond EM. Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia. Genes (Basel). 2015;6:935-956. [PMID: 26426056 DOI: 10.3390/genes6040935] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
409 Tan HW, Sim AY, Huang SL, Leng Y, Long YC. HC toxin (a HDAC inhibitor) enhances IRS1-Akt signalling and metabolism in mouse myotubes. J Mol Endocrinol 2015;55:197-207. [PMID: 26373795 DOI: 10.1530/JME-15-0140] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
410 Sharifi-Rad J, Sharifi-Rad M, Hoseini-Alfatemi SM, Iriti M, Sharifi-Rad M, Sharifi-Rad M. Composition, Cytotoxic and Antimicrobial Activities of Satureja intermedia C.A.Mey Essential Oil. Int J Mol Sci 2015;16:17812-25. [PMID: 26247936 DOI: 10.3390/ijms160817812] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
411 Infante P, Alfonsi R, Botta B, Mori M, Di Marcotullio L. Targeting GLI factors to inhibit the Hedgehog pathway. Trends in Pharmacological Sciences 2015;36:547-58. [DOI: 10.1016/j.tips.2015.05.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
412 Padige G, Negmeldin AT, Pflum MK. Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors. J Biomol Screen 2015;20:1277-85. [PMID: 26232305 DOI: 10.1177/1087057115598118] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
413 Gu R, Liu T, Zhu X, Gan H, Wu Z, Li J, Zheng Y, Dou G, Meng Z. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application. J Chromatogr B Analyt Technol Biomed Life Sci 2015;1000:181-6. [PMID: 26245362 DOI: 10.1016/j.jchromb.2015.07.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
414 Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol Sci 2015;36:481-92. [PMID: 26013035 DOI: 10.1016/j.tips.2015.04.013] [Cited by in Crossref: 137] [Cited by in F6Publishing: 136] [Article Influence: 19.6] [Reference Citation Analysis]
415 Yoon YK, Ali MA, Wei AC, Choon TS, Shirazi AN, Parang K. Discovery of a potent and highly fluorescent sirtuin inhibitor. Med Chem Commun 2015;6:1857-63. [DOI: 10.1039/c5md00307e] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
416 Fang C, Wang Y, Li Y. [Research Progress of Histone Deacetylase Inhibitor Combined with 
Immune Checkpoint Inhibitor in the Treatment of Tumor]. Zhongguo Fei Ai Za Zhi 2021;24:204-11. [PMID: 33819971 DOI: 10.3779/j.issn.1009-3419.2021.102.11] [Reference Citation Analysis]